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V Summary
Interstitial  lung diseases (ILD)  or  diffuse parenchymal  lung diseases (DPLD)  are  a 
heterogenous group of chronic disorders that affect the distal lung. They are largely 
unresponsive to any currently available therapy and lead to architectural distortion of 
the lung parenchyma and rapid respiratory failure. The pathogenesis of the disease is 
not completely understood. In some ILDs like the idiopathic pulmonary fibrosis (IPF) 
the initial alveolar epithelial cell injury followed by ER-stress and apoptosis of alveolar 
epithelial cells type II (AECII) seems to be the triggering factor. 
Collagen  vascular  diseases  (CVD)  are  a  group  of  immunologically  mediated 
inflammatory disorders affecting predominantly the connective tissue and the vessels, 
however,  quite  frequently,  also  the  lung.  Especially  in  Polymyositis  (PM), 
Dermatomyositis (DM) and Systemic Sclerosis (SSc), ILD determines morbidity and 
mortality of  the disease.  Autoantibody expression seems to be highly predictive for 
pulmonary involvement. An autoantibody frequently found in PM/DM is anti  histidyl-
tRNA-Synthethase  (anti-HisRS),  most  specific  autoantibodies  in  SSc  are  anti-
Topoisomerase1  (anti-Topo1),  anti-Topoisomerase2α  (anti-Topo2α) and  anti-
Topoisomerase2β (anti-Topo2β). 
In the present project it was hypothesized that autoantibodies cause development of 
ILD in CVD via alveolar  epithelial  cell  injury leading to an ER-stress and apoptotic 
response in AECIIs. We supposed that the binding of pathogenetic antibody directed 
against  HisRS and  topoisomerases  results  in  a  loss  of  function  of  the  respective 
proteins, which again causes aleveolar epithelial cell injury. 
In order to evaluate such proposed mechanism, HisRS, Topo1, Topo2α and Topo2β 
were silenced via siRNA transfection  in vitro in A549 cells. Furthermore, inhibition of 
topoisomerases  was  performed  in  vitro  by  treating  A549  cells  with  topotecan  and 
etoposide.  ER-stress  and  apoptosis  were  analyzed  employing  Western  Blot, 
semiquantitative RT-PCR and quantitative RT-PCR.
In  vitro  knockdown  experiments  (siRNA mediated)  for  HisRS,  Topo1,  Topo2α  and 
Topo2β did not result in ER-stress or increased apoptosis markers. On the other hand it 
was  shown  that  ER-stress  and  apoptosis  occur  in  A549  cells  after  inhibition  of 
topoisomerases with topotecan or etoposide. Performing immunohistochemistry of lung 
sections of  a patient with SSc associated ILD revealed ER-stress and apoptosis in 
AECIIs. These results suggest that autoantibodies found in CVD may contribute to the 
development of ILD by causing ER-stress and apoptosis in AECIIs.      
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VI Zusammenfassung 
Die  interstitiellen  Lungenerkrankungen  (englisch:  ILD-  interstitial  lung  disease)  sind 
eine  heterogene  Gruppe  von  chronischen  Lungenerkrankungen,  die  das  periphere 
Lungenparenchym betreffen. Im Falle einiger ILDs wie der idiopathischen pulmonalen 
Fibrose  (IPF)  sind  diese  überwiegend  therapierefraktär,  führen  zu  Zerstörung  der 
Architektur des Lungenparenchyms und rasch zu respiratorischem Versagen. 
Obwohl  die  Pathogenese  der  Erkrankung  größtenteils  ungeklärt  ist,  lassen  neue 
Studien  gerade  bei  der  so  ungünstigen  IPF  eine  initiale  Schädigung  von 
Alveolarepithelzellen (AEC) vermuten, woraufhin es zu ER-Stress und Apoptose von 
Alveolarepithelzellen Typ II (AECII) kommt. 
Bei  Kollagenosen,  einer  Gruppe  von  Autoimmunerkrankungen,  die  sich  bei 
systemischem Befall vorwiegend an Bindegewebe und Blutgefäßen abspielen, stellt die 
Entwicklung  einer  ILD  eine  nicht  seltene  Komplikation  dar.  Vor  allem  bei  den 
Kollagenosen Polymyositis  (PM),  Dermatomyositis  (DM)  und systemischer  Sklerose 
(SSc) bestimmt wesentlich das Vorhandensein einer ILD die Morbidität und Mortalität 
der  Erkrankung.  Die  pulmonale  Beteiligung  ist  mit  dem  Auftreten  spezifischer 
Autoantikörper (AAk) assoziiert. Bei PM/DM handelt es sich um AAk gegen Histidyl-
tRNA-Synthethase (HisRS), spezifische AAk bei SSc sind gegen die Topoisomerase1, 
2α und 2β (Topo1/2α/2β) gerichtet.
Für das hier vorliegende Projekt wurde die Hypothese aufgestellt,  dass die AAk zur 
Pathogenese  der  ILDs  in  Kollagenosen  beitragen,  indem sie  das  alveoläre  Epithel 
schädigen im Sinne eines ER-Stress und so zur  Apoptose der  AECIIs  führen.  Wir 
postulierten,  dass  die  Bindung  der  spezifischen  Autoantikörper  an  HisRS  und  die 
Topoisomerasen zu einem Funktionsverlust der jeweiligen Proteine führt  und so ein 
Schaden im Bereich des alveolären Epithels verursacht wird. 
Daher  wurden  die  Zielgene  der  genannten  AAk  in  vitro  in  A549  Zellen  mit 
entsprechenden  siRNA  gehemmt.  Außerdem  wurde  ein  Funktionsverlust  der 
Topoisomerasen  durch  Behandlung  von  A549  Zellen  mit  Topotecan  und  Etoposide 
erzielt.  Mittels  Western  Blot,  semiquantitativer  und  quantitativer  PCR  wurden 
anschließend ER-Stress- und Apoptose-Marker analysiert.  
Die in vitro Hemmung der AAk durch eine siRNA Transfektion ergab keinen deutlichen 
Effekt bezüglich ER-Stress und Apoptose. Allerdings konnte gezeigt werden, dass nach 
der Inhibition von Topoisomerasen durch Topotecan und Etoposide eine deutliche ER-
stress-  und  Apoptose-Antwort  in  A549  Zellen  stattfindet.  Im  Rahmen  der 
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immunhistochemischen Untersuchung von Lungenschnitten eines Patienten mit  SSc 
assoziierter ILD hinsichtlich zellulärer Stressmuster konnten ER-Stress und Apoptose 
in den AECIIs dargestellt werden.  
Die vorliegenden Ergebnisse legen die Vermutung nahe, dass die in Assoziation  mit 
genannten  Kollagenosen  auftretenden  AAk  die  Entwicklung  von  ILDs  vermitteln 
können, indem sie ER-Stress und Apoptose in AECIIs auslösen.     
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1. Introduction
     
1.1 Interstitial lung diseases 
Interstitial  lung diseases (ILD)  or  diffuse parenchymal  lung diseases (DPLD)  are a 
group of more than 100 different conditions mainly affecting the pulmonary interstitium, 
the alveolar epithelium and the capillary endothelium [1]. Characteristic features of ILD 
include increase of connective tissue which leads to fibrosis, reduced lung compliance 
and impaired gas exchange [2]. ILDs present  an important  cause of  morbidity and 
mortalitiy worldwide. In the late stages of the disease patients develop a cor pulmonale. 
Respiratory failure is the most common reason for lethal outcome of the disorder  [3]. 
Figure 1 shows a schematic of the general classification of the ILDs [4]. 
Figure 1: A schematic for the general classification of the DPLDs [4]
IPF – idiopathic pulmonary fibrosis, NSIP – non-specific interstitial pneumonia, RBILD – respiratory bronchiolitis interstitial  
lung disease, DIP – desquamative interstitial pneumonia, AIP – acute interstitial pneumonia, COP – cryptogenic organizing 
pneumonia
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The complexity of classification of ILD arises from the heterogenity of the diesease.  As 
shown in Figure 1 ILD includes either diseases with a well-defined cause such as an 
inhalational (e.g. asbestosis),  a drug-induced (e.g. amiodarone) or a granulomatous 
(e.g. sarcoidosis) etiology. ILDs also occur in association with systemic disorders like 
vasculitis,  reno-pulmonary syndromes and collagen vascular  diseases (CVD). Some 
ILDs lack  an obvious origin,  e.g.  the idiopathic  interstitial  pneumonia (IIP).  The IIP 
presents  the  most  common  form  of  ILD  [1].  In  2002  the  American  Thoracic 
Society/European Respiratory Society (ATS/ERS) established a classification of IIPs 
which  was  updated  in  2013  [5].  Combining  clinical,  imaging  and  histopathological 
information, the classification of IIP now distinguishes between major IIPs, rare IIPs, 
and unclassifiable IIPs.  The major  IIPs are grouped into chronic  fibrosing IPs,  that 
include  idiopathic  pulmonary  fibrosis  (IPF)  and  non-specific  interstitial  pneumonia 
(NSIP),  smoking-related  IPs  comprising  respiratory  bronchiolitis–interstitial  lung 
disease (RB-ILD) and desquamative interstitial pneumonia (DIP), and acute/subacute 
IPs  including  cryptogenic  organizing  pneumonia  (COP)  and  acute  interstitial 
pneumonia (AIP) [5]. 
The  revised  classification  emphasized  the  importance  of  an  integrated  clinical, 
radiological  and  pathological  approach  because  of  the  improved  diagnostic 
possibilities, such as the high resolution computed tomography (HRCT) and the less 
invasive lung biopsy via video-assisted thoracic surgery (VATS). The recognition that 
many of the ILDs have distinctive HRCT- appearances has greatly reduced the need 
for lung biopsy [1]. Already in 2011, ATS/ERS published evidence-based guidelines for 
diagnosis and management of IPF and specified that lung biopsy is not an essential 
criteria for a final diagnosis of IPF anymore in case of a definite UIP pattern in HRCT 
[6,7].  In such case, the diagnosis is correct in more than 90% cases, showing that 
surgical  biopsy   is  no  longer  justified  in  the  appropiate  clinical  setting  [8,9,10]. 
Nevertheless in  some cases when HRCT pattern is not  explicit,  lung biopsy is  still 
needed for final diagnosis.  Table 1 describes typical histologic patterns and HRCT 
appearances of the most frequent ILDs [3].  
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Table 1: Classification of histological and radiological patterns developed for IIP [3]
Chest  HRCT  and  lung  function  tests  are  the  most  useful  diagnostic  items  in 
establishing the clinical significance of an ILD. The interstitial abnormalities occuring in 
ILDs are associated with a restrictive pattern in lung function. Proportional reduction in 
forced vital capacity (FVC) and forced expiratory volume in the first second (FEV1) are 
detected, next to an impaired diffusion capacity, measured as a reduction in diffusing 
capacity of the lung for carbon monoxide (DLCO). DLCO is the most sensitive marker 
of ILD [11].
1.2 ILD in collagen vascular diseases 
Collagen  vascular  diseases  (CVDs)  are  a  heterogenous  group  of  autoimmune 
inflammatory disorders which include systemic sclerosis (SSc), dermatomyositis (DM), 
polymyositis  (PM),  systemic  lupus  erythematosus,  rheumatoid  arthritis,  sjögren 
syndrome  and  mixed  connective  tissue  disease  [12].  Pulmonary  involvement  is  a 
common, and occassionally the first manifestation in CVDs. Therefore an autoimmune 
screen is advised in all patients who present with ILD [13]. Especially in patients with 
SSc and PM/DM, the prevalent developement of ILD represents a significant cause of 
morbidity and mortality [14,15]. The pathogenesis of lung fibrosis in CVDs is still not 
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completely  understood,  but  the  involvement  of  an  autoimmune  background  is 
hypothesized [16]. The high prevalence of lung fibrosis in patients with CVDs suggests 
a correlation between existence of autoantibodies and developement of lung fibrosis 
[17,18].  Bringing  this  correlation  into  focus  may  offer  a  chance  to  get  a  better 
understanding  of  the  pathogenesis  of  ILD  in  order  to  develop  new  therapeutical 
options.  UIP and NSIP,  two histopathologic  patterns of  the IIPs,  are also the most 
frequent histological patterns of  ILD in SSc and PM/DM [19,20].  UIP describes the 
histopathologic pattern of IPF.  A combination of histological patterns is quite frequent in 
the context of CVDs [13], especially a mixture of UIP and NSIP pattern can be detected 
frequently [21]. Therefore it is important to introduce the most important forms of IIP´s, 
namely IPF and NSIP. 
1.3 Idiopathic pulmonary fibrosis 
IPF represents the most common form of IIPs with the worst prognosis and a mean 
survival of 2–3 years after diagnosis [22,23]. It mostly affects people over 50 years of 
age and is more common in males. Typical clinical manifestations of IPF are dyspnea, 
nonproductive  cough,  bibasilar  fine  inspiratory  crackles,  a  restrictive  impairment  of 
pulmonary function and dysfunction of gas exchange [23]. The pathogenesis of IPF 
remains unknown. Epithelial cell damage and apoptosis of alveolar epthelial cells type 
II (AECII) seem to be the triggering events for proliferation and activation of fibroblasts 
which transform into myofibroblasts and cause excessive production of extracellular 
matrix  (ECM)  which  ultimately  leads  to  fibrosis  [22,24–26].  As  shown  in  Figure  2, 
typical  imaging  features  include  subpleural  reticular  opacities  and  traction 
bronchiectasis  that  increase from the apex to  the bases of  the  lungs  [27-30].  UIP 
describes  the  histopathological  pattern  of  IPF.  As  shown  in  Figure  3  important 
histologic  features  are  temporal  and  spacial  heterogenity,  resulting  in  still  regular 
appearing  areas  next  to  disease-defining  areas,  microscopic  honeycombing  and 
fibroblast foci consisting of activated fibroblasts [27].
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(a)  IPF is  characterized by heterogeneous lung abnormalities  consisting of  subpleural  honeycombing (arrowhead), 
reticular  opacities,  and  traction  bronchiectasis. (b)  NSIP  demonstrates  homogeneous  lung  involvement  with 
predominance of ground-glass opacity combined with subpleural linear opacities and micronodules. The microcysts in 
NSIP (arrowhead) are much smaller than the honeycombing in UIP. [28]
(a) Photomicrograph (original magnification, 40; hematoxylin-eosin stain) shows patchy fibrosis with remodeling of the 
lung architecture. Interstitial chronic inflammation is mild, with only a few lymphoid aggregates (thin arrow). Cystically  
dilated airspaces that produce a honeycomb pattern (arrowhead) and areas of relatively unaffected lung (thick arrow) 
are present. (b) Photomicrograph (original magnification, 200; hematoxylin-eosin stain) shows a fibroblastic focus of 
loose organizing connective tissue (arrowheads). [28]
Figure 3: Histologic features of UIP [28]
a b
Figure 2: Comparison of high-resolution CT features between UIP and NSIP [28]
a      
   
b
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Because of its devastating character it is important to differentiate between IPF and 
other ILDs. In 2011 the American Thoracis Society (ATS), the European Respiratory 
Society  (ERS),  the  Japanese  Respiratory  Society  (JRS),  and  the  Latin  American 
Thoracic Association (ALAT) published  evidence-based guidelines for diagnosis and 
management of  IPF  [6].  It  was determined, that diagnosis of  IPF requires following 
points:
• Exclusion of other known causes of ILD.
• The presence of an UIP pattern on HRCT in patients non subjected to surgical 
lung biopsy.
• Proof of IPF on the basis of HRCT (probable UIP; inconsistent with IPF) and 
surgical  lung  biopsy  (UIP by  histological  criteria)  in  patients  subjected  to  a 
surgical lung biopsy.  [6]
In the last years treatment of IPF was a subject of many studies. The aim of treatment 
is to prevent disease progression. Therapies targeting the antifibrotic and growth factor 
pathways  are  currently  being  developed.  Pirfenidone,  a  novel  antifibrotic  and 
antiinflammatory drug,  was  first  licensed in  Europe for  IPF treatment  in  2011,  and 
results in attenuation of  disease progression  [31,32]. Moreover, Nintedanib, a novel 
triple-kinase inhibitor targeting receptors of fibrolast growth factor, vascular endothelial 
growth factor and platelet-derived growth factor seems to be another promising drug in 
attenuation of progression of IPF and was just licensed for treatment in IPF in 2015 
[33]. Nevertheless lung transplantation still remains the only effective therapeutic option 
for  patients  suffering  from advanced  IPF  [1,34,35].  Previous studies  have reported 
conflicting survival rates for UIP in CVD compared to those in IPF. Interestingly some 
clinical studies suggest that an UIP pattern in CVD-related disease is associated with a 
significantly better survival rate compared to  UIP pattern in the idiopathic setting [36]. 
In contrast to this recently Esam et al.  demonstrated that the outcome of CVD-UIP 
patients is similar to IPF/UIP patients [37].   
1.4 Nonspecific interstitial pneumonia
With  a  mean survival  of  6-8  years  after  diagnosis,  idiopathic  nonspecific  interstitial 
pneumonia (NSIP) has a better prognosis than IPF [23]. The mean age of patients at 
the onset of NSIP is about ten years younger than patients with IPF. Neither sexual 
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predominance nor connection with cigarette smoking could be established [3]. NSIP 
pattern  is  strongly  associated  with  collagen  vascular  diseases,  exogenous  allergic 
alveolitis (EAA) and drug-induced lung fibrosis, but NSIP can occur as an idiopathic 
disease too [23,38].  Next to dyspnea and cough, fatigue and weight loss are usual 
symptoms.  Abnormalities  in  lung function  are  similar  to  those in  UIP but  are  often 
milder [3]. Pathogenesis of NSIP is still not defined [39]. The histopathologic pattern 
shows varying combinations of inflammation and fibrosis, sometimes predominated by 
chronic  interstitial  inflammation,  named  „cellular  NSIP“,   sometimes  by  interstitial 
fibrosis,  the  „fibrotic  NSIP“  [19,38].  But  the role  of  inflammation as the preceeding 
trigger for the development of  NSIP is more emphasized than in IPF [3,40]. As shown 
in  Figure  2  temporal  and  spacial  homogenity  is  an  important  difference  to  UIP.  In 
contrast to IPF ground glas opacitiy (GGO) combined with scattered micronodules exist 
frequently in NSIP [23,28]. Usually no honeycomb changes or fibroblast foci can be 
detected in histopathological analysis [14]. 
(a) Photomicrograph (original magnification, 100; hematoxylin-eosin stain) of cellular NSIP shows a uniform appearance 
of  interstitial  inflammation  (arrow),  which  consists  of  lymphocytes  and  plasma cells.  (b) Photomicrograph (original 
magnification, 100; hematoxylin-eosin stain) of fibrosing NSIP shows areas of fibrosis (arrow) in addition to uniform 
inflammation. [28] 
The treamtment of NSIP is similar to the one of IPF. In patients with SSc-related NSIP 
Cyclophosphamid  is  considerered  the  most  promising  agent  available  today  [41]. 
Consideration should also be given to oxygen therapy and treatment of  pulmonary 
hypertension [1]. 
Figure 4: Histologic features of NSIP [28]
a      
   
b
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1.5 Molecular mechanisms underlying IPF and NSIP
The  exact  mechanisms  responsible  for  initiation  and  perpetuation  of   ILD  remain 
elusive [19,27]. According to a more recent hypothesis, epithelial cell injury followed by 
ER-stress induced apoptosis seem to be the triggering events in pathogenesis of IPF 
[2,3,22,42]. Failure to re-epithelialize the injured alveolar epithelium leads to disruption 
of the epithelial integrity in the alveoli and release of profibrotic cytokines and growth 
factors, that causes proliferation of fibroblasts, abnormal collagen deposition and finally 
leads to decline of lung function and impairment in gas exchange [42-44]. Increased 
apoptosis of AECIIs was observed at an early stage of the disease, not only in areas of 
remodelled regions replaced by fibrous tissue but also frequently  in  regions of  lung 
with  almost normal appearing  alveolar structures [24,26,45]. Supporting this concept 
we previously demonstrated that a severe ER Stress response in the AECIIs underlies 
the programmed cell death in patients with IPF [42].
The older hypothesis that the development of IPF is due to chronic inflammation thus 
has been replaced by the hypothesis of epithelial cell injury. Yet, especially in cellular 
NSIP,  the  histolopathologic  pattern  is  often  predominated  by  chronic  interstitial 
inflammation and inflammation may still play a significant role [14,38]. 
Therefore it has been suggested that the inflammatory concept should not be excluded 
from the pathogenesis of lung fibrosis, but rather be seen as an associating factor next 
to the alveolar epithelial injury [44]. 
1.5.1 Role of AECII in development of lung fibrosis
Chronic injury of AECIIs is considered as the key in pathophysiology of IPF [22,46]. 
AECIIs synthesize, secrete and recycle all components of surfactant. Surfactant is a 
lipoprotein  complex  that  covers  the  alveolar  interface and  thereby reduces surface 
tension,  which is  necessary for  breathing at  normal  transpulmonary pressures.  The 
surfactant  proteins  SP-B  and  SP-C  are  key  components  of  surfactant  [47,48].  To 
prevent  infections  AECIIs  also  produce  compounds  of  the  innate  immune defense 
system, like SP-A [49]. Furthermore AECIIs have a high potential to proliferate [48,50] 
and show self-renewal  characteristics  [51,52].  And yet  they seem to be chronically 
injured in IPF. Risk factors for alveolar epithelial cell injury include smoking, exposure 
to metal or wood dust and genetic disposition, as well as age [6]. In familial forms of 
IPF and NSIP, mutations of surfactant proteins SP-A and SP-C, which are associated 
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with AECII injury and apoptosis, as well as mutations of members of the telomerase 
and  shelterin complex, which primarily cause DNA damage, have been disclosed [53–
55].  UIP,  the  histological  pattern  of  IPF,  can  also  be  seen  in  Hermansky-Pudlak 
syndrome  –  associated  interstitial  pneumonia  (HPSIP),  which  occurs  in  ~40%  of 
patients with Hermansky-Pudlak syndrome (HPS), a disease caused by a lysosomal 
transport  deficiency  affecting  the  whole  body.  Mahavadi  et  al.  [56]  found,  that  a 
defective  intracellular  surfactant  transport  in  AECII  underlies  lysosomal  stress, 
apoptosis and development of HPSIP. 
There are different theories under discussion regarding the mechanisms how injury of 
the AECIIs results in lung fibrosis. One of the theories involves epithelial-mesenchymal 
transition  (EMT),  where  epithelial  cells  undergo  a  transdifferentiation  into  activated 
fibroblasts.  Another  theory  suggests,  that  the  injured  AECIIs  lose  control  over  the 
mesenchymal  cells,  which  leads  to  proliferation  and  production  of  more  collagen. 
Furthermore it has been shown that a number of pro-fibrotic coumpounds are released 
by chronically injured AECIIs [47].
1.5.2 Endoplasmic reticulum (ER) -Stress and apoptosis
The  endoplasmic  reticulum  (ER)  is  a  subcellular  compartment.  Besides  calcium 
storage and release and lipid biogenesis it plays a central role in protein synthesis and 
folding [57].  Impairment  of  protein  folding and processing leads to accumulation of 
unfolded proteins  in  the ER,  which triggers the so called  unfolded protein respone 
(UPR)  in  order  to  restore  ER  functions  [58].  UPR  increases  protein  folding  and 
processing  capacity  [59].  UPR  signaling  is  initiated  by  the  three  transmembrane 
proteins  inositol-requiring  enzyme  1α (IRE1α),  the  protein  kinase RNA-like 
endoplasmic reticulum kinase (PERK) and the activating transcription factor 6 (ATF6) 
[60]. PERK phosphorylates the alpha unit of the eukaryotic initiating factor 2 (eIF2α) 
which reduces the protein load on the ER. IREα induces splicing of  x-box binding 
protein 1 (XBP1) mRNA in order to produce the homeostatic transcription factor XBP1s 
[61].  ATF6 and XBP1s increase transcription of  genes which enhance ER size and 
function [62].   By phosphorylation of eIF2α the translation of activating transcription 
factor 4 (ATF4) is stimulated that again leads to transcription of different pro-survival 
genes [63]. However if ER-stress is too severe and prolonged, apoptosis is induced via 
ATF4-dependent  upregulation  of  C/EBP  Homologous  Protein  (CHOP)  transcription 
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factor [60,64].  It is reported that CHOP induces cell cycle arrest and apoptosis [65].
ER-stress  has  been  implicated  in  the  pathogenesis  of  many  neurodegenerative 
disorders  like  Alzheimer´s,  Parkinson´s  and  Huntington´s  disease  and  amyotrophic 
lateral sclerosis, as well as in acute pathological states of the brain as ischemia and 
trauma [64].  ER-stress has also been found to be caused by the above mentioned 
mutations of SP-A and SP-C in familial IPF [47]. Of late, a study from Korfei et al.  [42] 
focussing on sporadic  cases of  IPF has demonstrated the importance of  ER-stress 
driving the AECII apoptosis. 
1.6 Collagen vascular diseases 
Collagen vascular diseases (CVD) represent a heterogenous group of immunologically 
mediated disorders. The pathomechanism of these diseases is yet not fully settled, but 
the  obvious  dysregulation  of  the  immune  system  results  in  the  synthesis  of 
autoantibodies affecting  predominantly the connective tissue and the vessels. A large 
variety of  organs may be affected. As mentioned before CVDs include SSc, PM/DM, 
systemic  lupus  erythematosus,  rheumatoid  arthritis,  sjögren  syndrome  and  mixed 
connective tissue disease [12]. In the following sections, PM/DM and SSc will be the 
CVDs of interest in view of their frequent pulmonary involvement.    
1.6.1 Polymyositis and Dermatomyositis
PM is characterized by inflammation and degeneration primarily of the muscles. Clinical 
signs  are  symmetrical  proximal  muscle  weakness,  tenderness,  pain  and  ultimately 
atrophy  and  fibrosis  of  the  muscle.  Furthermore  myalgies  and  inflammation  of 
pharyngeal muscles are common manifestations [66,67]. Appropiate diagnostic criteria 
are  raised  muscle  enzymes,  muscle  biopsy  consistant  with  a  myositis  and 
characteristic electromyographic alterations [68]. Additional to the clinical symptoms of 
PM, DM is clinically defined by characteristic cutaneous signs such as photosensitive 
erythroedema, orbital erythema, erythematosus or violaceous plaques on the dorsal 
surface of interphalangeal and metacarpophalangeal joints, called Gottron´s papules, 
and periungual erythema, the so called manicure sign [67,69]. PM and DM often occure 
in overlap with other CVDs [68]. PM and DM are associated with serum autoantibodies, 
some of which are detected almost exclusively in these diseases. The most specific 
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antibody  is  the  antibody  directed  against  histidyl-tRNA-Synthethase  (anti-HisRS) 
[18,66,70].
(a)  Facial  erythroedema [71]  (b)  Gottron´s  papules:  Erythematosus plaques on the surface of  interphalangeal  and 
metacarpophalangeal joints, hyperkeratosis of proximal nail fold [72] (c) Periungual erythema („manicure sign“) [73]
1.6.1.1 Jo-1 syndrome
The  Jo-1  syndrome  describes  a  subgroup  of  PM/DM and  is  characterized  by  the 
presence of anti-HisRS (=anti-Jo-1) autoantibodies and specific clinical manifestations. 
In  addition  to  myositis,  patients  suffer  from  lung  fibrosis,  chronic  polyarthritis, 
Raynaud´s phenomenon and fever. ILD is an early diagnostic sign [74,75].
                  Episodic vasospasm as response to cold or emotional stress [76]
1.6.1.2 Lung involvement
Lung fibrosis is one of the most common extramuscular manifestations in PM/DM and 
Figure 5: Dermatomyositis – Typical cutaneous signs [71-73]
a. b.
c.
Figure 6: Raynaud syndrome [76] 
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a common cause of morbidity and mortality in these patients [77]. ILD (histologically 
NSIP or UIP) is found in approximately 30% of the patients with PM and in over 60% of 
the patients with Jo-1 syndrome [14,75,78]. Arthritis or arthralgia, next to old age (>45 
years), are significantly associated with ILD  [79,80]. The existence of autoantibodies 
also  correlates  with  pulmonary  manifestation.  Antibodies  against  aminoacyl-tRNA 
synthetases have been tigthly linked to the development of ILD. Autoantibody against 
histidyl-tRNA-Synthethase  (anti-HisRS)  is  the  most  common  antibody  against 
aminoacyl-tRNA and  shows a  strong  association  with  pulmonary  involvement.  It  is 
detected  in  30-75% of  PM/DM associated  ILD  [13] and  consequently  serves as  a 
marker of PM/DM associated ILD [12,81,82].
1.6.1.3 Autoantibody against histidyl-tRNA-Synthethase 
The antibody considered most specific for PM/DM is the antibody against histidyl-tRNA-
Synthethase (anti-HisRS = anti-Jo-1) [83]. Anti-HisRS exists in 10-30% of patients with 
PM/DM and is one of the conditions for the diagnosis Jo-1 syndrome. Anti-HisRS is 
directed  against  HisRS  and  thus  probably  inhibits  its  function.  HisRS  synthesizes 
histidyl-transfer RNA, that is fundamental for the incorporation of histidine into proteins. 
The amino acid histidin plays an important role in many catalytic functions of enzymes. 
Enzymatic decarboxylation of histidine generates the biologically important histamine. 
Furthermore  HisRS belongs  to  the  group  of  aminoacyl-tRNA synthetases  that  can 
synthesize diadenosine tetraphosphate. Diadenosine tetraphosphate is suspected to 
be involved in several regulatory mechanisms of cell  metabolism [84].  A cleaveable 
form  of  HisRS  was  detected  in  the  lung,  especially  in  alveolar  epithelium,  which 
suggests, that autoimmunity to HisRS is initiated in the lung and thus maybe plays an 
important role in the developement of lung fibrosis [82]. 
1.6.2 Systemic sclerosis
Systemic sclerosis (SSc) is an autoimmune disease of unknown etiology that involves 
tissue ischemia and fibroproliferative changes in the skin and internal organs [85]. For 
the classification of SSc major and minor criteria exist. SSc is diagnosed if one major, 
and two or more minor criteria are present: 
Major criterion:  Symmetrical  thickening, tightening,  and induration of  the skin of the 
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fingers  and  the  skin  proximal  to  the metacarpophalangeal,  or  metatarsophalangeal 
joints.
Minor criteria:  1. Sclerodactyly: the changes of the major criterion, but limited to the 
      fingers                                                                        
                       2. Digital pitting scars or loss of substance from the finger pad: 
     depressed areas at tips of fingers or loss of digital pad tissue as a 
      result of ischemia                        
                         3. Bibasilar pulmonary fibrosis  [86]
SSc  can  be  divided  into  three  subgroups,  diffuse  cutaneous  systemic  sclerosis 
(dcSSc),  limited  cutaneous  systemic  sclerosis  (lcSSc)  and  systemic  sclerosis  sine 
scleroderma  (ssSc).  DcSSc  is  characterized  by  generalized  skin  affection  and 
involvement of internal organs. In lcSSc skin induration is limited to hands, face and 
feet. LcSSc is also known as CREST-Syndrom, which is characterized by calcinosis 
cutis, raynaud syndrome, esophageal dysmotility, sclerodactyly and teleangiectasia. In 
ssSc internal organs are affected without any cutaneous involvement [85,87].  SSc is 
associated with the presence of antinuclear antibodies (ANAs), which are for example 
directed against Topoisomerase 1 (anti-Topo1=anti-SCL-70) and Topoisomerase 2α/β 
(anti-Topo2α/β) [88]. 
(a) Microstoma with actinomorphic wrinkles, teleangiectasia [89]  (b) Sclerodactyly: thickening, tightening and induration 
of the skin of the fingers [90] (c) Erythema and crusted squames at the tips of the fingers [91] 
1.6.2.1 Lung involvement
Lung  involvement  is  one  of  the  most  common  manifestations  in  SSc.  Data  for 
occurance of pulmonary disease in SSc differ from 50% to 90% [12,14,85,92,93]. ILD is 
the major form of pulmonary involvement associated with SSc and the leading cause of 
death [93]. Nevertheless the majority of SSc patients show relatively limited pulmonal 
Figure 7: Systemic sclerosis – Typical cutaneous signs [89-91] 
a. b.
c.
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disease, which remains stable even without treatment [13]. NSIP and UIP are the most 
common  histopathologic  patterns  [19,94,95].  Autoantibody-expression  against 
topoisomerases  in  SSc  can  be  considered  strongly  predictive  for  internal  organ 
involvement,  especially  for  the  development  of  ILD [12,86].  Autoantibodies  against 
topoisomerases (Anti-Topos) belong to the group of ANAs and are often associated 
with SSc. While anti-Topo1 is almost exclusively detected in SSc and highly predictive 
for  internal  organ  involvement,  anti-Topo2  can  be  found  in  different  autoimmune 
diseases like juvenile rheumatoid arthritis (14%), systemic lupus erythematosus (1,5-
31%) and systemic sclerosis (22%) [88].  
1.6.2.2 Function of topoisomerases
Because of the double helical structure of DNA the problem of torsional tension arises. 
Solving these topologic difficulties by untangling and untwisting DNA is essential for 
biologic  processes  like  replication,  transcription,  recombination  and  chromatin 
remodeling [96].  Topoisomerases are ubiquitous enzymes and play a crucial  role in 
modulating DNA topology by introducing temporary single or double strand breaks in 
dsDNA [88].  Topoisomerases generate  a  transient  phosphodiester  bond between a 
tyrosine  residue  in  the  protein  and  one  of  the  ends  of  the  broken  strand.  This 
intermediate break allows the DNA to be untangled. Thus topoisomerases can relief the 
torsional tension between the two strands of DNA during replication and are able to 
relax the supercoiling in the DNA during transcription [96]. There are different classes 
of topoisomerases. In the following Topoisomerase type 1 and type 2 will be examined. 
Topoisomerase 1 (Topo1) cleaves a single strand of DNA, no adenosine triphosphate 
(ATP)  is  necessary  for  the  reaction.  Topo1  supports  the  fork  movement  during 
replication and relaxes supercoils occurring during transcription [96,97].
                         
Figure 8: Schematic illustration of the action of Topoisomerase Type 1  [98]
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Topoisomerases 2 (Topo2) generate transient double strand breaks in the DNA, ATP is 
required  for  this  reaction.  Topo2  is  associated  with  gene  promotor  regions,  which 
suggests, that they somehow play a role in transcription activation [97]. Topo2 can be 
subdivided in  Topo2α and Topo2β,  based on structural  considerations.  The precise 
roles of the two types are subject of current studies. Topo2α is essential for all cells and 
seems to play an important role in solving the topological problems associated with 
mitosis and replication [99]. The Topo2β-mediated, transient dsDNA break is required 
for  activation  of  gene transcription  by nuclear  receptors  and other  classes of  DNA 
binding transcription factors like activator protein 1 (AP-1). Furthermore it is suggested, 
that the dsDNA break formation, generated by Topo2β, creates a signal that leads to 
the activation of a poly[adenosine diphosphate (ADP)-ribose] polymerase 1 (PARP-1). 
PARP-1  is  a  nicotinamide  adenide  dinucleotide  (NAD+)-  dependent  enzyme  that 
detects and repairs damage to the DNA. Thus Topo2β probably regulates the initiation 
of ligand-or signal-dependant gene transcription [97]. 
  
                                                               
(a)  Reactions  catalysed  by  Topo2  include  decatenation  of  linked  intact  double  stranded  DNA and  relaxation  of 
supercoiled DNA. (b) Topo2 introduces a double strand break in one DNA strand, called G or gate segment and passes 
a second strand called T segment through the break. In the presence of Mg2+, the enzyme can cleave the DNA.  ATP 
binding enables the enzyme to form a closed clamp. The closed clamp may also capture another strand (the T strand) 
that will pass through the break made in the G strand. ATP hydrolysis occurs at two steps in the reaction. The first 
hydrolysed ATP may assist in strand passage. The second hydrolysis step allows the clamp to reopen. [99]
Figure 9: Schematic illustration of the action of Topoisomerase Type 2 [99]
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2. Aim of the study
Lung fibrosis is a common manifestation in PM/DM and SSc and the major cause of 
death in these diseases [15,19,75]. Autoantibodies against HisRS, Topo1, Topo2α and 
Topo2β are  highly  predictive  for  the  appearence  of  lung  involvement  [12,81,82,88] 
suggestive of a correlation between the existence of autoantibodies and developement 
of  ILD  in  PM/DM and  SSc.  We therefore  wished  to  explore  the  possibilitiy  of  an 
autoantibody induced blockade of  HisRS,  Topo1,  Topo2α or  β  in  alveolar  epithelial 
cells, possibly resulting in chronic AECII injury and apoptosis.  We supposed that the 
binding of pathogenetic antibody directed against HisRS and topoisomerases results in 
a loss of function of the respective proteins and hence asked:
• Does  in  vitro  knockdown  of  HisRS,  respectively  Topo1,  Topo2α  and 
Topo2β provoke an ER Stress or apoptotic response in AECIIs? 
• Can AECII specific induction of ER-stress be shown in patient with SSc 
associated ILD? 
To answer these questions, the following approaches were considered: 
• Silencing of HisRS, Topo1, Topo2α and Topo2β in A549 cells via siRNA and 
analysis of ER-stress and apoptosis.
• Inhibition of  Topo1, Topo2α and Topo2β in A549 cells via treatment with the 
inhibitors topotecan and etoposide and analysis of ER-stress and apoptosis. 
• Immunohistochemical  analysis  of  ER-stress  in  lungs  of  a  patient  with  SSc 
associated ILD compared to healthy donor lungs.  
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3. Material and Methods
    
3.1 Materials
3.1.1 Cell line
   
For all experiments a A549 cell line was used. A549 cells are adenocarcnomic human 
alveolar basal epithelial cells which can be used as an in vitro model of AECII.
3.1.2 Human lung sections
Immunohistochemistry  was  performed  on  serial  paraffin-embedded  tissue  sections 
from one human patient  with  SSc  associated  ILD and compared  to  healthy donor 
sections.  Lung sections  were applied  by the Biobank of  the  european IPF registry 
(eurIPFreg) and belong to the patients´ collective of Gießen. There is a vote of the 
ethical  review  committee  of  the  Justus-Liebig-Universität  Gießen  regarding  the 
eurIPFreg (AZ: 111/08). Histopathologic examination was performed by the department 
of pathology Universitätsklinikum Gießen und Marburg.      
3.1.2.1 Patient data
Lung tissue sections of patient with SSc-ILD were obtained from a male patient born in 
1954. Lung transplantation was performed in 2010. Diagnosis of SSc was settled by 
performing  skin  biopsy  and  barium  swallow  examination  of  the  eosopagus,  here 
scleroderma and disturbance in eosophagus-motility could be found. Lung fibrosis was 
diagnosed  by  performing  lung  function  test,  HRCT and  lung  biopsy.  Lung  function 
revealed a severe restrictive dysfunction of the lung.  In HRCT, an UIP pattern was 
demonstrated.  Lung  biopsy  confirmed  UIP also  histopathologically.  In  addition,  an 
elevated  titer  of  ANA´s  (1:640)  was  detected.  Further  differentiation  of  the 
autoantibodies was not possible. 
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3.1.3 Machines / Software
MJ Mini Personal Thermal Cycler BioRad, USA
Nanodrop ND-100 spectrophotometer Nanodrop Technologies, USA
Trans-Blot SD Semi-dry Transfer Cell BioRad, USA
My iQᵀᴹ Single Color Real-Time PCR Detection 
System
BioRad, USA
iQ5 Optical System Software BioRad, USA
SPECTRAFlour Plus Tecan
Magellan Tecan Inc. Software Tecan
Molecular Imager Gel Doc™ XR BioRad, USA
Image Lab Software BioRad, USA
HiTrap Protein G HP column GE Healthcare, Sweden
Table 2: Machines / Software
3.1.4 Reagents
3.1.4.1 Chemicals and reagents
Acetic Acid Merck, Darmstadt, Germany
Acrylamide solution, Rotiphorese Gel 30 Roth, Karlsruhe, Germany
Agarose Roth, Karlsruhe, Germany
Albumin Roth, Karlsruhe, Germany
APS  Roth, Karlsruhe, Germany
Bromphenol Blue Merck, Darmstadt, Germany
BSA Roth, Karlsruhe, Germany
β-Mercaptoethanol Sigma Aldrich, Steinheim, Germany
D-MEM GIBCO Invitrogen, Germany
DMSF Merck, Darmstadt, Germany
EDTA Sigma Aldrich, Steinheim, Germany
EtBr SERVA Electrophoresis GmbH, 
Heidelberg, Germany
Ethanol 70%, 95%, 99.6% Fischer scientific, Germany
etoposide Calbiochem, EMD Chemicals, San Diego, 
USA
FCS PAA Laboratories GmbH, Marburg, 
Germany
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Glutamin GIBCO Invitrogen, Germany
Glycerol mounting medium Dako cytomation, Hamburg, Germany
Glycine Roth, Karlsruhe, Germany
 Haemalaun Roth, Karlsruhe, Germany
HCL Roth, Karlsruhe, Germany
Methanol Fluka Chemie, Buchs, Switzerland
NaCl Roth, Karlsruhe, Germany
Na-Deoxycholat Fluka Chemie, Buchs, Switzerland
Paraformaldehyde Fischer scientific, Germany
PBS PAA Laboratories GmbH, Marburg, 
Germany
PenStrep GIBCO Invitrogen, Germany
 PMSF (Proteinaseinhibitor) SERVA Electrophoresis GmbH, 
Heidelberg, Germany
Saccharose Roth, Karlsruhe, Germany 
SDS Merck, Darmstadt, Germany
Skim Milk Powder Fluka Chemie, Buchs, Switzerland
Sodium Hydroxide Solution (NaOH) Merck, Darmstadt, Germany
Thapsigargin GIBCO Invitrogen, Germany
TEMED Fluka Chemie, Buchs, Switzerland
topotecan Hydrochloride Hydrate Sigma Aldrich, Steinheim, Germany
Tris Roth, Karlsruhe, Germany
Triton X-100 Sigma Aldrich, Steinheim, Germany   
Tween-20 Sigma Aldrich, Steinheim, Germany
Xylene Roth, Karlsruhe, Germany
Table 3: Chemicals and biochemicals
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3.1.4.2 Transfection reagents
reagent company/catalog number
DharmaFECT non-targeting siRNA Thermo Fisher Scientific, Germany
siGENOME Control Reagent Thermo  Fisher Scientific, Germany
HisRS siRNA Santa Cruz Biotechnology, Germany, 
sc-37675
Topo I siRNA Santa Cruz Biotechnology, Germany, 
sc-36694
Topo IIα siRNA Santa Cruz Biotechnology, Germany,
sc-36695
Topo IIβ siRNA Santa Cruz Biotechnology, Germany, 
sc-36697
Table 4: Transfection reagents
            
                                                                                       
3.1.4.3 Antibodies
Primary antibody origin dilution company/catalog number
ATF4 (Creb2) rabbit 1:1000 (WB, IHC) Santa Cruz Biotechnology, 
Germany, sc-200
β-Actin rabbit 1:15000 (WB) Abcam, USA, ab8226
CHOP (GADD 153) mouse 1:2000 (WB) Abcam, USA, ab11419
CHOP rabbit 1:50 (IHC) Sana Cruz Biotechnology, 
Germany 
Cleaved Caspase 3 rabbit 1:125 (WB) Trevigan, catalog: 2305-PC-
100
HisRS mouse 1:100 (WB) Santa Cruz Biotechnology, 
Germany, sc-81287
LC3B rabbit 1:1000 (WB) Abcam, USA, ab48394
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Pro SP-C rabbit 1:500 (IHC) Chemicon, USA
P50 ATF6 rabbit 1:1000 (WB)
1:100 (IHC)
Abcam, USA
Topo1 mouse 1:1000 (WB) Santa Cruz Biotechnology, 
Germany, sc-32736
Topo2α mouse 1:500 (WB) Santa Cruz Biotechnology, 
Germany, sc-165986
Topo2β rabbit 1:2000 (WB) Abcam, USA, ab72334
Topo2β rabbit 1:2000 (WB) Bethyl Laboratories, Texas, 
catalog: A300-949A
Table 5: primary antibodies
Secondary antibody origin dilution company
Polyclonal Rabbit anti Mouse 
Immunglobulins/HRP
rabbit 1:1000 Dako, Denmark
Polyclonal Swine anti Rabbit 
Immunglobulins/HRP
swine 1:2000 Dako, Denmark
                                Table 6: Secondary antibodies                                      
3.1.4.4 Buffer
Protein extraction:  50mM Tris, pH=7.5
5mM EDTA 
150mM NaCl
1% (w/v) Triton x-100
0.5% (w/v) Na-Deoxycholat
1mM PMSF
DNA agarose gel electrophoresis:  
• 1x TAE buffer: 40 mM Tris-acetate, pH = 8.0
     1 mM EDTA, pH = 8.0
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Western Blot analysis:
 
• Seperating Gel buffer: 1.125M Tris
pH 8.8
30% Saccharose
• Stacking Gel buffer: 0.625M Tris
pH 6.8
• 4x SDS-loading buffer: 5g SDS
40ml glycerin 
25ml stacking gel buffer 
0.01g bromophenolblue 
for a final volume of 100ml      
     
• SDS-Running buffer / Electrode 
buffer 10:
Tris 25mM
Glycine 192 mM
SDS 0.1%
• Transfer buffer: 20mM Tris
159mM Glycine
20% MeOH
• Wash buffer: TBS-T 10x 1M Tris
4M NaCl
1% Tween-20
pH 7.5
• Block solution: Skim Milk Powder 5%
TBS-T 1x
• Stripping buffer: TBS-T 1x
2% SDS
100mM β-mercaptoethanol
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IgG-Purification: 
• Binding buffer: 0.1M Glycine buffer, pH 9.0                    
0.1M Glycine buffer, pH 2.5-2.7
1M Tris-HCL buffer, pH 9.0
IHC:   
• permeabilization buffer: 0.4%  Triton  X-100  in  
1xPBS
pH 7.4  
3.1.4.5 Gels
Agarose gel: 2% Agarose
1xTAE buffer
0.5 μg/μl EtBr
Seperating Gel:          
8% 9% 10% 12% 15%
A. dest. 3.87ml 3.53ml 3.20ml 2.53ml 1.53ml
1.125 M Tris, pH 8.8  3.33ml  3.33ml  3.33ml 3.33ml  3.33ml
Acrylamide/Bisacrylamide 
(30%/0.8%)
 2.66ml      3.0ml  3.33ml      4.0ml      5.0ml
10% SDS    100μl  100μl   100μl   100μl   100μl
TEMED     10μl    10μl      10μl        10μl      10μl
10% APS     50μl    50μl     50μl      50μl      50μl
Table 7: Seperating Gel
Stacking Gel:                                                
A.dest.  6.57ml
0.625M Tris, pH 6.8    2.0ml
Acrylamide/Bisacrylamide (30%/0.8%)  1.33ml
10% SDS   100μl
TEMED     10μl
10% APS   100μl
Table 8: Stacking Gel
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3.1.4.6 Kits
Products Manufacturer
Zytochem AP  fast  red  kit, broad spectrum Zytomed systems, Berlin, Germany.
BCA protein assay kit Pierce, Germany.
iQ(ᵀᴹ) SYBR Green Supermix BioRad, USA.
Omnitranscript RT Kit (200) Qiagen, Hilden, Germany.
HotStarTaq DNA Polymerase Kit Qiagen, Hilden, Germany.
Phire Hot Start II DNA Polymerase Finnzymes (Thermo Scientific), Espoo, 
Finland.
RNeasy Pus Mini Kit (50) Qiagen, Hilden, Germany.
Table 9: Kits
3.2 Methods
          
3.2.1 Cell culture
    A459 cells were cultured in D-MEM:F12, supplied with 10% FCS, 2mM Glutamin, 1% 
Penicillin, 1% non-essential amino acids and 1% MEM Vitamins in an atmosphere of 
95-100 % air humidity, 5% CO2 at 37 °C. Passaging was carried out in a confluent 
stadium. After one washing step with 1x PBS, 3.5 ml of Trypsin/EDTA was added until 
the  detachment  of  the  cells  from  the  underlay  was  catalyzed.  Removing  the 
Trypsin/EDTA and  adding  2ml  of  Medium  stopped  this  process.  By  pipetting  the 
Medium several times up and down, the cells were stripped from the plate. In order to 
split the cells in a dilution of 1:20 or 1:10, 100μl or 200μl of the cell suspension was 
added  to  a  new  plate,  containing  10ml  of  Medium.  To  use  the  cells  for  further 
experiments they were seeded accordingly to respective protocols.  
3.2.2 siRNA Transfection
In order to analyze the consequence of a loss of function of specific genes on RNA and 
protein level, the technique of small interfering RNA (siRNA) was used. siRNA consists 
of short double strand ribonucleic molecules and is directed against a complementary 
gene  sequence  that  is  meant  to  be  silenced.  It  enters  the  cell  via  lipid-based 
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transfection and binds the so called RNA-induced silencing complex (RISC). RISC is a 
ribonucleoprotein complex which has not  been completely identified yet.  Nucleases 
such  as  Dicer,  Argonaute  proteins  and  a dsRNA-binding  protein  (dsRBP)  play  an 
important role in this complex.  Binding the RISC leads to a separation of the RNA 
strands  and  an  activation  of  the  complex.  The  activated  RISC/siRNA-complex 
associates with the complementary mRNA and cleaves it. Thus the translation of the 
target mRNA can be inhibited and the expression of the specific gene is silenced [100]. 
For silencing, cells were plated in a 6-well-plate and incubated until they reached more 
than 90% confluency.  In  order to  prepare a 20µM stock solution,  each siRNA was 
resuspended in RNase free water. Cells transfected with non targeting siRNA served 
as a negative control. To exclude a potential effect of transfection reagent on the cells, 
a mock transfection (transfection with transfection reagent without any siRNA) was also 
included. To get a 2µM siRNA working solution, the 20µM stock solution was diluted 
1:10 in PBS. The preparation of the transfection reagents was calculated for triplicate 
transfection. Solution A, consisting of 350µl siRNA working solution plus 350µl serum 
free medium, was carefully mixed wih a pipette and incubated at RT for 5min.  For 
solution B 28µl of transfection reagent Dharmafect and 672µl of serum free medium 
were carefully mixed with a pipette. After a 5min incubation at RT, solution A was added 
to solution B,  carefully mixed with a pipette and incubated for 20min.  Finally 5.6ml 
serum containing culture medium was added to this solution. For mock transfection, 
solution A was prepared with PBS instead of siRNA solutions. Medium was removed 
from the cells and 2ml/well of siRNA solution was added. Cells were harvested after 
48h, 72h or 96h respectively.
3.2.3 Protein Inhibition
In  order  to  inhibit  activity  of  topoisomerases,  the  protein  inhibitors  etoposide  and 
topotecan were used. 
Etoposide  is  a  semisynthetic  derivative  of  podophyllotoxin  that  exhibits  antitumor 
activity. It causes error in DNA synthesis and prevents re-ligation of DNA strands by 
forming a complex with Topo2 and DNA. Thus repair of DNA by Topo2 is inhibited and 
apoptosis of cancer cells can be promoted [101].
Topotecan is an antineoplastic agent used to treat ovarian cancer. It works by inhibiting 
function  of  Topo1.  Topotecan  binds  to  the  Topo1-DNA-complex  and  thus  prevents 
religation of the single strand breaks [102–104].
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To prepare a stock solution of 100µM of protein inhibitors, respective amounts were 
solved in 200µl Dimethylsulfoxide (DMSO) and filled up with culture medium to 50ml. 
Cells  were  treated  with  protein-inhibitor-solution  in  different  concentrations  and  at 
different  time  points.  After  treatment  endpoints  cells  were  harvested  and  protein 
expression was checked by Immunoblotting.
Medium containing only DMSO without inhibitors served as vehicle. 
In order to get a positiv control for apoptosis and ER-stress some cells were treated 
with a 1µM solution of Thapsigargin instead of etoposide or topotecan. Thapsigargin is 
an enzyme known for triggering apoptosis and ER-stress.
        
3.2.4 Protein extraction and quantification
After  transfection  or  inhibition  endpoints,  proteins  were  lysed  in  100µl  lysis  buffer. 
Plates were dipped twice in liquid nitrogen for a few seconds and harvested with a cell 
scraper. The suspensions were transfered to Eppendorf tubes.  After destroying DNA 
with  Sono  Rex  the  tubes  were  centrifugated  at  4°C  and  13000rpm for  5min.  The 
supernatant  was  obtained  and  used  for  protein  concentration  determination  by 
Bicinchoninic acid (BCA) method, a colorimetric detection system of cuprous cation. A 
BCA/copper complex is formed which exhibits  a  linear  absorbance at  562nm with 
increasing protein concentrations. To construct a standard curve 2mg/ml bovine serum 
albumin (BSA) was mixed with 0.9% NaCl respectively in order to get different dilutions 
of BSA (1500µg/ml,  1000µg/ml, 750µg/ml, 500µg/ml, 250µg/ml, 125µg/ml, 62.5µg/ml, 
31.25µg/ml, 15.625µg/ml, 7.813µg/ml). For the measurement BSA solutions and 1:10 
diluted protein probes were transfered in duplication to a 96 well plate and mixed with 
200µl of Pierce BCA dye. After 45min incubation at 37°C absorbance was measured at 
565nm  in  a  ELISA  plate  reader.  The  corresponding  protein  concentrations  were 
calculated by interpolation using the standard curve.
         
3.2.5 Polyacrylamide Gel Electrophoresis of Protein (SDS-Page)
In order to perform Western Blot analysis, protein extracts were seperated by SDS 
polyacrylamide gel electrophoresis (SDS-Page). SDS denatures the proteins and binds 
to the polypeptides. Thus a negative charge to the polypeptides is provided that leads 
to  the  migration  of  the  polypeptides  to  the positive  electrode.  The mobilitiy  of  the 
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proteins increases linear  to the protein size.  The smaller  the molecule the faster  it 
migrates. In this way protein can be seperated according to their molecular weight. 
Proteins  were  mixed  with  4x  SDS-loading  buffer  reduced  by  adding  10% β-
mercaptoethanol  and denatured in a water bath at 98°C for 15min. The  samples were 
collected  by  brief  centrifugation. After loading a proteinladder and 20µg or 25µg of 
each  protein  sample  onto  the  gel  (stacking  and  seperating  gel  were  produced  as 
described in table 7 and 8), electrophoresis was performed in presence of SDS-running 
buffer at 90V till the bromphenol blue reached the bottom of the seperating gel. 
3.2.6 Immunoblotting
The  separated  proteins  on  the  SDS  polyacrylamide  gel  were  transfered  to  a 
polyvinylidene  fluoride  (PVDF)  membrane  by  electro  blotting  to  visualize  specific 
proteins. The PVDF membrane was activated with methanol before using. Two layers 
of  Whatmann  3mM  filter  paper  washed  with  Transfer  buffer  followed  by  PVDF 
membrane were placed onto the electroblotting chamber. On the PVDF membrane, the 
gel and two other filter paper washed with Transfer buffer were placed. The transfer 
was performed at constant current (2mA/cm²) for 1.5h. After this step the membrane 
was blocked in 5% Skim Milk solution for 1h at RT. To dissolve the Skim Milk Powder, 
TBSTx1 was used. After blocking respective primary antibodies, diluted in 5% Skim 
Milk, were added to the membrane  and incubated at 4°C overnight. Concentrations of 
different antbodies are listed in table 5 . The next day the membrane was washed in 
TBSTx1 4 times for 15min, followed by incubation with appropriate secondary antibody 
(refer to table 6) at RT for 1h. After washing with TBSTx1, the protein was detected by 
ECL (Enhanced Chemi-luminescence) treatment and exposure of  the membrane to 
ECL  films  in  dark.  Bands  on  the  film  were  finally  visualized  by  diping  them  in 
developing and fixing solutions. Where necessary, the membranes were re-probed with 
another antibody by stripping it with stripping buffer at 58°C for 2h. After washing with 
TBSTx1 and blocking with 5% Skim Milk at RT for 1h, appropriate primary antibody 
was added, followed by further steps as described before. 
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3.2.7 Densitometry
To perform densitometric analysis, the spot denso software from Alpha Innotech was 
used. Values of  target  protein were normalized to actin values and are given as a 
percentage of the respective scrambled controls. 
3.2.8 RNA isolation and measurement
Isolation of RNA from A549 cells was performed by using the RNeasy Pus Mini Kit (50). 
Steps were accomplished according to the instructions of the manufacturer. Obtained 
RNA solutions were stored at -80°C. Concentration and purity of the obtained RNA was 
determined  with  a  Nanodrop  ND-100  spectrophotometer  via  measuring  the  optical 
density at 260nm and 280nm of the obtained solutions. The wavelenght for maximal 
absorption of nucleid acids is 260nm, known as Optical Density at 260nm (OD260nm). 
An  OD of  1  at  260nm  corresponds  to  40µg  RNA/ml.  Proteins,  that  often  form  a 
contamination source, have an absorption maximum of 280nm (OD280nm). Therefore 
the quotient of the OD at 260nm and at 280nm is a measure of RNA purity. In a pure 
RNA  and  protein-free  solution  the  ratio  OD260nm/280nm  is  2.  Due  to  protein 
contaminations this coefficient is usually lower. In the experiments of this study it was 
between 1.8 and 2.
                
3.2.9 cDNA synthesis     
In  order  to  perform semiquantitave reverse transcription  polymerase chain  reaction 
(sqRT-PCR)  or  quantitative  reverse  transcription  PCR  (qRT-PCR),  RNA  was 
transcribed into comlentary cDNA using the Omnitranscript RT Kit (200). The reverse 
transcription of mRNA to cDNA is catalyzed by reverse Transcriptase (RT) and RNA-
dependent DNA polymerase. By using Oligo dT-Primer, which hybridize to the poly(A) 3
´tail of mRNA all mRNAs could be primed simultaneously. 
For  the  preparation  of  cDNA,  2µg  RNA was  used.  For  20μl  reaction  11µl  of  the 
following master mix was added to 2µg/9µl RNA. For 40μl reaction 22μl of the following 
master mix was added to 2μl/18μl RNA.
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reagent 20μl reaction 40μl reaction
10x Buffer 2μl 4μl
dNTPs (5mM each dNTP) 2μl 4μl
Oligo-dT Primer (10 μM) 0.5μl 1μl
RNAse Inhibitor (10 units/μl) 0.5μl 1μl
Reverse Transcriptase (4 units/μl) 1μl 2μl
RNase free water 5μl 10μl
Table 10: Master mix for reverse Transcription
Reverse transcription was performed in a Thermo Cycler, using the following protocol:
1. Attachment of the Oligo-dT Primer 25°C for 10min
2. Reverse Transcription 37°C for 65min
3. Cooling 4°C
Table 11: Protocol for reverse transcription
      Obtained cDNA was stored at -20ºC.  
      
3.2.10 Reverse transcription polymerase chain reaction (RT-PCR) 
PCR is a method which allows the amplification of DNA sequences in order to detect 
them. This procedure uses two specific oligonucleotides, which function as primers, 
four deoxyribonucleotide triphosphates (dNTP´s) and a heat-stable DNA polymerase. 
Each   reaction  cycle  consists  of  three  reactions  that  take  place  under  different 
temperatures:
1. Denaturation at 94°C: The double-stranded DNA is converted into two single 
strands.
2. Hybridization at 50-65°C: Cooling of the reaction allows the annealing of the 
primers to the complementary DNA sequence.
3. DNA synthesis  at  72°C:  thermo-stable  DNA polymerase  extends  both  DNA 
strands starting from the primers.
In 20-50 reaction cycles the target DNA product increases exponentially and can be 
detected. PCR products were analysed either semiquantitatively or quantitatively.
3. Material and Methods                                                                             30 
3.2.10.1 Semiquantitative reverse transcription polymerase chain reaction 
Semiquantitative reverse transcription polymerase chain reaction (sqRT-PCR) analyzes 
the PCR products via gelelectrophoresis, it is an endpoint determination.
For sqRT-PCR following PCR-Mix was used:
HotStarTaq DNA Polymerase Kit:
reagent 25μl reaction
d10xBuffer      2.5μl
NTP (10 mM of each)     0.5μl
forward primer (10 pM)        1μl
reverse primer (10 pM)        1μl
H2O 17.75μl
Taq-Polymerase (5 units/μl)   0.25μl
cDNA (20μl reaction)        2μl
Total volume      25μl
Table 12: PCR-Mix for sqRT-PCR (HotStarTaq DNA Polymerase)
The PCR was performed in a thermo-cycler, programmed as follows:
Activation  of  HotStart 
Taq
20min 94°C
Denaturation 30cycles 30s 94°C
Annealing 30s Refer to table 18
Extension 1min 72°C
Final Extension 10min 72°C
Table 13: Cycle protocol for sqRT-PCR (HotStartTaq DNA Polymerase)
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Phire Hot Start II DNA Polymerase:
reagent     25μl reaction
PhireBuffer        5μl
DNTPs (10 nM)      0.5μl
forward primer (10 pM)        2μl
reverse primer  (10 pM)        2μl
H2O      13μl
Taq-Polymerase (5 units/μl)     0.5μl
cDNA (40μl reaction)       2μl
Total volume     25μl
Table 14: PCR-Mix for sqRT-PCR (Phire Hot Start II DNA Polymerase)
The PCR was performed in a thermo-cycler, programmed as follows:
Activation of  Phire 
Hot Start II 
Polymerase
30s 98°C
Denaturation 25cycles  5s 98°C
Annealing  5s Refer to table 18
Extension 15s 72°C
Final Extension 1min 72°C
Table 15: Cycle protocol for sqRT-PCR (Phire Hot Start II Polymerase)
                 
After amplification PCR products were analyzed via agarose gel electrophoresis. 
3.2.10.2 Quantitative reverse transcription polymerase chain reaction 
Unlike  the  sqRT-PCR,  which  is  an  endpoint  analysis  of  the  PCR  products,  the 
quantitative  reverse  transcription  polymerase  chain  reaction  (qRT-PCR)  performs 
simultaneous  quantification  of  the  initial  amount  of  amplified  sequence  next  to  the 
amplification. The process is monitored in „real time“, means products are measured 
during the reaction and at the end of each cycle respectively. For this, fluorescent dyes, 
which conduct proportional to the product accumulation, are used [105].
Following PCR-Mix was used:
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reagent 20µl reaction
BIORAD Sybergreen Mix  10µl 
forward primer 10 pmol/µl 0.5µl
reverse primer 10pmol/µl 0.5µl
water    8µl
cDNA (10ng/µl)    1µl
Table 16: PCR-Mix for qRT-PCR
                                                                        
The PCR was performed with iQᵀᴹ Single Color  Real-Time PCR Detection System 
programmed as follows:
1x 3min 95°C
Denaturation 40 cycles 15s 95°C
Annealing 30s 58°C 
1x 10s Meltingcurve analysis
Table 17: Cycle-protocol for qRT-PCR
  
3.2.10.3 DNA agarose gel electrophoresis
DNA agarose gel electrophoresis is used to analyze DNA fragments obtained in sqRT-
PCR. Agarose gelelectrophoresis can seperate and visualize DNA fragments according 
to their size. An electric field causes a movement of negatively charged DNA from the 
cathode  (-)  to  the  anode  (+).  After  a  certain  time  period  shorter  molecules  have 
covered a longer distance than longer ones,  as the shorter  molecules move faster 
through the gel. For the electrophoresis a 2% agarose gel was prepared with 1xTAE 
buffer mixed with respective amounts of agarose. To visualize DNA, the gel was treated 
with 0,5µg/ml ethidium bromide (EtBr). EtBr intercalates between the bases of DNA 
double strands and fluoresces under ultraviolet light. The DNA sample was mixed with 
5x loading buffer and 10µl of this solution was loaded onto the agarose gel that was 
covered  by  1xTAE buffer.  Electrophoresis  was  performed for  45-60min  at  80V/cm. 
Finally the gel was visualized with Molecular Imager Gel Doc™ XR system. The size of 
amplified DNA was determined by a DNA molecular weight standard.   
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3.2.10.4 Measurement of fluoresecence with SYBR-Green
Measurement of fluorescence is necessary to analyze products obtained during qRT-
PCR. One possibility of detection is to measure the fluoresecence with SYBR-Green, a 
dsDNA-specific asymmetric cyanine dye. It binds sequence independently to the minor 
groove of dsDNA. The fluoresecence of the bound dye is 1000-fold higher than that of 
free  dye,  which  is  the  reason  why  product  accumulation  during  PCR can  be  well 
monitored.  Fluoresecence is measured at  the end of the elongation phase of each 
cycle,  when the amount of  dsDNA reach their  maxima and fluoresecence is  at  the 
highest point. It is possible, that non-specific products like primer dimer occur, which 
alters  the  amplification  efficiency.  This  can  lead  to  a  quantification  error  and  the 
quantitative analysis has to be optimized [105].
                                     
3.2.10.5 Melting curve analysis  
SYBR Green binds to any dsDNA. Melting of the product means, that SYBR-Green is 
released and fluoresecence signal  decreases rapidly.  A melting curve identifies the 
PCR product because of temperatue-dependant signal decrease as a result of melting 
of the product. The melting temperature  (Tm) is defined as the temperature at which 
the decrease of temperature occurs and half of the DNA is present as a denatured 
single strand. Tm is characterized by the lenght of the dsDNA. After the PCR cycles 
were performed, the samples were heated to 95°C. This leads to denaturation of the 
samples  and thus an abrupt  decrease of  fluorescence.  Timepoint  of  fluoresecence 
decline  allows  the  conclusion  of  Tm.  Nonspecific  products  have  deviating  melting 
temperatures. For example primer dimers have a lower melting temperature as they 
are shorter. Thererfore the amplification of the correct sequence can be confirmed. The 
area under the curve (AUC) of the peak is proportional to the product amount [105].
3.2.10.6 Analysis of data
To analyze the data, the fluroscence signal is plotted against  the number of cycles 
(amplifiaction plot). The baseline of this graph is determined by the initial phase that 
corresponds to the cycles in which the fluroescence has not yet started to increase 
considerably. The crucial point for quantification is the exponential phase of product 
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accumulation,  the so-called “threshold“  regarding the fluorescence signal  has to be 
assessed.  The  cycle  number  when  the  signal  reaches  this  threshold  is  called  Ct 
(theshold  cycle)  or  crossing  point.  It  depends  linear  on  the  logarithm  of  the  inital 
product concentration and therefore allows its determination. 
For the comparative Ct method of relative quantification to be valid, the efficiency of the 
reaction  of  the  target  gene  and  the  efficiency  of  the  reaction  of  the  reference/ 
housekeeping  gene  must  be  approximately  equal.  Amplification  efficiancy  was 
determined by running serial dilutions of a template, the results were used to generate 
a standard curve. Amplification efficiency was calculated from the slope of the standard 
curve. Ideally, the amount of PCR product will perfectly double during each cycle of 
exponential  amplification.  This  translates  to  a  reaction  efficiency  of  2.  ß-Actin,  an 
ubiquitously  and  constitutively  expressed  gene  in  human  cells  was  used  as  a 
reference/ housekeeping gene. 
In order to get a relative quantification of the mRNA level of the target gene, their Ct 
values were analyzed as the difference to the housekeeping gene:  ∆Ct = Ct house 
keeping gene – Ct target gene. β-Actin was used as the housekeeping gene. To judge 
the  effects  of  silencing  on  gene  expression,  mRNA  level  changes  of  samples 
transfected  with  non  targeting  siRNA (Scrambled)  were  compared  with  untreated 
samples (UT), mock transfections (Mock) and samples transfected with target siRNA. 
The difference was expressed as  ∆∆Ct and determined as follows:  ∆∆Ct UT = ∆Ct 
Scrambled  -  ∆Ct  UT;  ∆∆Ct  Mock=∆Ct  Scrambled  -  ∆Ct  Mock;  ∆∆Ct  siRNA=∆Ct 
Scrambled -  ∆Ct  siRNA.  The ∆∆Ct  corresponds to the binary logarithm of  the  fold 
change. 
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Primer Annealing Temperature 
(Hot Star Taq Polymerase)
Annealing Temperature
(Phire Hot Start II Polymerase)
ATF4 62°C 65°C
β-Actin 60°C 62°C
CHOP 60°C 65°C
DDB1 61°C 63°C
HisRS 58°C 61°C
PPIB 60°C 63°C
Topo1 60°C 63°C
Topo2α 61°C 63°C
Topo2β 59°C 59°C
VCP 62°C 65°C
XBP1 (first set) 61°C 64°C
XBP1 (second set) 60°C 62°C
Table 18: Annealing Temperatures
                       
3.2.11 Immunohistochemistry
Immunohistochemistry (IHC) is the localization of antigens in tissue sections by the use 
of labeled  antibody  as  specific  reagents  through  antigen-antibody interactions that 
are  visualized by a marker such as fluorescent dye, enzyme, radioactive element or 
colloidal  gold. Since immunohistochemistry involves specific antigen-antibody reaction, 
it  has   apparent  advantages  over  other  traditionally  used  special  enzyme  staining 
techniques  that   identify  only  a  limited  number  of  proteins,  enzymes  and  tissue 
structures. There are  numerous immunohistochemistry methods that may be used to 
localize antigens. The selection of a suitable method should be based on parameters 
such  as  the  type  of   specimen  under  investigation  and  the  degree  of  sensitivity 
required. Lungs were fixed  in paraformaldehyde and sections of 3μm thickness were 
used for immunohistochemical  analysis in this study. Sections were deparaffinized at 
60°C for 2 hours and then in xylene for 10 minutes. They were then rehydrated in 
descending  alcohol  concentrations  (99.6%>96%>80%>70%>50%).  Sections   were 
washed  in  washing  buffer (1x PBS) to  remove traces of ethanol. Heat mediated 
antigen retrival was performed by boiling the section for 3x5 minutes at 500W, followed 
by washing in PBS. The AP fast red kit (Zytomed Berlin) was used for further steps. 
The sections were blocked for 10 minutes in the blocking  solution followed by washing. 
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Primary antibody solutions were prepared in 3% BSA solution with respective dilutions. 
A negative  control  was  always  used  where  primary  antibody  was  omitted.  Isotype 
controls served as confirmation of the specifity of used antibodies (Fig. 25 of appendix). 
For this purpose samples were incubated with antibody diluent, supplemented with a 
non-immune immunoglobulin of  the same isotype and concentration as the primary 
antibody.  Sections  were  placed  in  a  humid  chamber  and  incubated  with  primary 
antibody  overnight  at  4°C,  followed  by  washing  for  5  times.  50μl  of  biotinylated 
secondary  antibody  was  added  to  each  section  and  incubated  for  10  min  at  RT, 
followed  by  washing.  Few  drops  of  enzyme  conjugate  (streptavidin  /  alkalic-
phosphatase conjugate) were added to each section with 10 min incubation at  RT, 
followed  by  washing.  Fast  red  tablets  were  used  as  substrate  which  was  freshly 
prepared by dissolving one fast red tablet in one substrate buffer (naphtol-phosphate 
buffer). 50μl of this substrate solution was given to each section and allowed to develop 
in  the  dark,  with  constant  monitoring  for   the  pink  colour  development  under  light 
microscope. Enough care was taken that all  sections, control sections and negative 
control sections were treated in the same way, and  developed for the same time in 
order to avoid false results. After developing, the reaction  was stopped by immersing 
the slides in aqua.dest. Counterstaining was performed with haemalaun for 2 minutes 
followed by washing the slides under running tap water, which  resulted in blue nuclei. 
Sections were then mounted with glycerol mounting medium and allowed to dry. 
     
3.2.12 Statistical analysis
Unless otherwise stated, three independent experiments were conducted for all in vitro 
studies. Statistical significance was assessed employing Mann-Whitney U-test (Graph 
Pad Prism 4.0). Significance is indicated as # p < 0.05 between two different groups as 
indicated  in  the  respective  figure  legends.  Values  were  considered  not  significant 
where no symbols are indicated.  
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4. Results
4.1 Gene silencing in A549 cells
ER-stress induced apoptosis in AECII seems to represent a common pathomechanistic 
principle in ILD [9]. ER stress means a disruption of ER homeostasis which leads to 
accumulation of misfolded or unfolded proteins and is often followed by apoptotic cell 
death [60,64,106,107]. In order to investigate a possible relation between autoantibody 
expression  against  HisRS,  Topo1,  Topo2α and Topo2β  and  development  of  ILD, 
respective genes were silenced via siRNA transfection and occurance of ER-stress and 
apoptosis was checked in A549 cells.
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4.1.1 HisRS – Silencing and analysis of ER-stress and DNA-damage
4.1.1.1 HisRS - Silencing 
To assess the success of HisRS-Silencing on mRNA level, sqRT-PCR was performed 
after  72h  of  transfection.  PCR  products  were  visualized  by  DNA  agarose 
electrophoresis.  Downregulation  of  HisRS  mRNA after  transfection  with  a  specific 
siRNA directed against  HisRS could be shown (Fig.10a). To further corroborate the 
knockdown of HisRS, expression of the HisRS gene was quantified by qRT-PCR. The 
results are presented as mean of ∆∆CT ± SD The mRNA expression of HisRS after 
transfection  with  siRNA  was  significantly  decreased  (-3,93  ±  0.33),  proving  the 
knockdown (Fig.10b). Western blot analysis also showed a decrease in HisRS protein 
after siRNA transfection and thus confirms the success of HisRS-Silencing as well on 
protein level  (Fig.10c),  although there still  was HisRS protein visible.  Densitometric 
analysis from the immunoblots showed, that approximately 37% of HisRS is left post 
silencing (Fig. 10d). 
A549 cells were transfected with siRNA directed against HisRS, knockdown of HisRS was checked by RT-PCR and 
Immunoblot (IB) 72h after transfection. Mock (transfection with transfection reagent without any siRNA) and scrambled 
(non targeting) siRNA served as negative controls: Pictures are each representative for three independant experiments. 
(a) sqRT-PCR analysis for the expression of HisRS, 30 cycles were performed, β-Actin served as loading control. (n=3) 
(b) qRT-PCR analysis for the expression of HisRS, results are presented as mean of ∆∆CT ± SD (n=3; #p<0.05). (c) IB 
analysis for the expression of HisRS, β-Actin served as loading control. (n=3) (d) Densitometry was performed from IB 
analysis. The target protein/ß-Actin ratio was calculated (scrambled=100%) (n=3; # p<0.05). 
Figure 10: HisRS – Silencing
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4.1.1.2 Analysis of ER-stress and DNA-damage after HisRS knockdown
After successful silencing of HisRS, a possible existence of an ER-stress response, 
apoptosis or DNA-damage was investigated. For this purpose markers involved in ER-
stress such as CHOP [60,64,65],  Peptidyl-prolyl cis-trans isomerase B (PPIB) [108], 
Valosin containing protein (VCP) [109], ATF4 [60,64,65] and XBP-1 [60,64], as well as 
the marker  DNA damage binding  protein  1  (DDB1),  which  indicates  DNA-damage, 
were analyzed. 
As evident from Figure 11, we could, however, not detect any kind of significant ER 
stress response or DNA damage on RNA as well as on protein level 48 and 72h after 
transfection. 
(a) sqRT-PCR analysis of CHOP, PPIB, VCP and DDB1 48h after transfection with siRNA directed against HisRS, 30 
cycles were performed, β-Actin served as control. (n=2) (b) sqRT-PCR analysis of ATF4, CHOP and XBP-1 (221/169bp: 
unspliced = inactive, 195/143bp: spliced = active) 72h after transfection with siRNA directed against HisRS, 30 cycles 
were  performed,  β-Actin  served  as  loading  control.  (n=2)  (c-d)  qRT-PCR analysis  of  ATF4  and  CHOP  72h  after 
transfection with siRNA directed against HisRS, results are presented as mean of ∆∆CT ± SD (n=3). Significance level 
was not reached. Pictures are each representative for two independant experiments. 
       
Figure 11: No ER-stress or DNA damage 72h after HisRS knockdown
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4.1.2 Topoisomerase 1 – Silencing and analysis of ER-stress 
4.1.2.1 Topoisomerase 1 – Silencing 
SiRNA mediated knockdown of Topo1 was checked in the same manner as for HisRS. 
After 72h of transfection with siRNA against Topo1, sqRT-PCR showed a decrease in 
Topo1 expression (Fig.  12a) and qRT-PCR (-3,2  ± 0,36) and western blot  analysis 
clearly confirmed the silencing of Topo1 (Fig. 12b+c), again with some residual Topo1 
being visible on protein level.  Densitometric  analysis  revelaed about 14% of  Topo1 
being left after silencing (Fig. 12d).
A549 cells were transfected with siRNA directed against Topo1, knockdown of Topo1 was checked by RT-PCR and IB 
72h after transfection. Mock (transfection with transfection reagent without any siRNA) and scrambled (non targeting 
siRNA) served as negative controls: (a) sqRT-PCR analysis for the expression of Topo1, 30 cycles were performed, β-
Actin served as loading control. (n=3) (b) qRT-PCR analysis for the expression of Topo1, results are presented as mean 
of ∆∆CT ± SD (n=3; #p<0.05). (c) IB analysis for the expression of Topo1, β-Actin served as loading control. (n=3) (d) 
Densitometry was performed from IB analysis. The target protein/ß-Actin ratio was calculated (scrambled=100%) (n=3; 
# p<0.05). Pictures are each representative for three independant experiments.
As shown in Figure 23a of the appendix a slight decrease of Topo1 expression on 
mRNA level could be observed already after 48h of transfection with siRNA against 
Topo1. 
Figure 12: Topoisomerase 1 – Silencing
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4.1.2.2 Analysis of ER-stress after Topoisomerase 1 knockdown 
After successfully silencing the Topo1, a possible existence of an ER-stress response 
was investigated. For this purpose ATF4, CHOP and XBP-1, which are markers that 
indicate ER-stress, were analysed. Knockdown of Topo1 did not result in a significant 
induction of ER stress marker 72h after knockdown (Fig. 13 a-c). 
(a) sqRT-PCR analysis of ATF4, CHOP, XBP-1 (221/169bp: unspliced = inactive, 195/143bp: spliced = active) 72h after 
transfection with siRNA directed against Topoisomerase 1, 30 cycles were performed, β-Actin served as loading control. 
(n=2) (b-c) qRT-PCR analysis of ATF4 and CHOP 72h after transfection with siRNA directed against Topoisomerase 1, 
results are presented as mean of ∆∆CT ± SD (n=3). Significance level was not reached. Pictures are each 
representative for two independant experiments.
Figure 13: No ER-stress after Topoisomerase 1 knockdown
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4.1.3 Topoisomerase 2α – Silencing and analysis of ER-stress 
4.1.3.1 Topoisomerase 2α – Silencing
After  72h  of  transfection  with  siRNA against  Topo2α  sqRT-PCR  revealed  a  slight 
decrease of  Topo2α expression (Fig.14a).  Analysis  of  qRT-PCR (-5,48 ± 0,06) and 
western  blot  corroborates  the  Topo2α-knockdown  by  showing  a  considerable 
downregulation  of  Topo2α  (Fig.14  b+c).  On  protein  level  (Fig.  14c),  there  was  no 
Topo2α visible anymore. In densitometric analysis only 0.88% of Topo2α were left after 
silencing with siRNA (Fig. 14d). 
A549 cells were transfected with siRNA directed against Topo2α, knockdown of Topo2α was checked by RT-PCR and IB 
72h after transfection. Mock (transfection with transfection reagent without any siRNA) and scrambled (non targeting 
siRNA) served negative controls: (a) sqRT-PCR analysis for the expression of Topo2α, 30 cycles were performed, β-
Actin served as loading control. (n=3)  (b) qRT-PCR analysis for the expression of Topo2α, results are presented as 
mean of ∆∆CT ± SD (n=3; #p<0.05; * indicates significance between siRNA Topo2α and scrambled). (c) IB analysis for 
the expression of Topo2α, β-Actin served as loading control. n=3 (d) Densitometry was performed from IB analysis. The 
target protein/ß-Actin ratio was calculated (scrambled=100%)  (n=3; # p<0.05).  Pictures are each representative for 
three independent experiments.
After 48h of transfection with siRNA against Topo2α a very modest decrease of Topo2α 
expression could be revealed after performing sqRT-PCR (Fig. 23b of appendix).
                                                            Figure 14: Topoisomerase 2α – Silencing
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4.1.3.2 Analysis of ER-stress after Topoisomerase 2α knockdown
After successfully silencing the Topo2α, a possible existence of an ER-stress response 
was  investigated.  For  this  purpose  ATF4,  CHOP  and  XBP-1  were  analysed.  As 
illustrated in Figure 15 sqRT-PCR analysis did not reveal any ER-stress response 72h 
after knockdown of Topo2α (Fig.15 a). Quantification of ATF4 and CHOP via qRT-PCR 
suggests a slight, but not significant ER-stress response after Topo2α-knockdown (Fig. 
15 b-c). 
(a) sqRT-PCR analysis of ATF4, CHOP, XBP-1 (221/169bp: unspliced = inactive, 195/143bp: spliced = active) 72h after 
transfection with siRNA directed against  Topoisomerase 2α,  30 cycles were performed,  β-Actin served as  loading 
control.  (n=2)  (b-c)  qRT-PCR  analysis  of  ATF4  and  CHOP  72h  after  transfection  with  siRNA directed  against 
Topoisomerase 2α, results are presented as mean of ∆∆CT ± SD ( #p<0.05). Values were considered not significant 
where no symbols are indicated. Pictures are each representative for two independent experiments. 
Figure 15: No ER-stress after Topoisomerase 2α knockdown
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4.1.4 Topoisomerase 2β – Silencing and analysis of ER-stress  
4.1.4.1 Topoisomerase 2β – Silencing
Transfection with siRNA against Topo2β was performed for 72h followed by analysis of 
Topo2β expression on mRNA and protein level.  SqRT-PCR and qRT-PCR (-6,05 ± 
0,46) as well as western blot analysis showed a clear downregulation of Topo2β and 
thus confirmed successfully silencing of Topo2β (Fig.16a-c). In densitometric analysis 
magnitude  of  remaining  protein  was  measured  approximately  22.5%,  given  as  a 
percentage of the respective scrambled controls (Fig. 16d).  
A549 cells were transfected with siRNA directed against Topo2β, knockdown of Topo2β was checked by RT-PCR and IB 
72h after transfection. Mock (transfection with transfection reagent without any siRNA) and scrambled (non targeting 
siRNA) served as negative controls. (a) sqRT-PCR analysis for the expression of Topo2β, 30 cycles were performed, β-
Actin served as loading control. (n=3) (b) qRT-PCR analysis for the expression of Topo2β, results are presented as 
mean of ∆∆CT ± SD (n=3; #p<0.05). (c) IB analysis for the expression of Topo2β, β-Actin served as loading control.
(n=3)  (d)  Densitometry  was  performed  from  IB  analysis.  The  target  protein/ß-Actin  ratio  was  calculated 
(scrambled=100%) (n=3;  # p<0.05). Pictures are each representative for three independent experiments. 
Figure  23c  of  appendix  shows  a  downreglation  of  Topo2β  in  sqRT-PCR after 
transfection with siRNA directed against Topo2β already after 48h of transfection. 
                                                           Figure 16: Topoisomerase 2β – Silencing
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4.1.4.2 Analysis of ER-stress after Topoisomerase 2β knockdown
Despite a successful knockdown of Topo2β no increase in ER-stress markers ATF4, 
CHOP or sXBP-1 could be observed in sqRT-PCR and RT-PCR analysis 72h after 
transfection (Fig.17 a-c). 
(a) sqRT-PCR analysis of ATF4, CHOP and XBP-1 (221/169bp: unspliced = inactive, 195/143bp: spliced = active) 72h 
after transfection with siRNA directed against Topoisomerase 2β, 30 cycles were performed, β-Actin served as loading 
control.  (n=2)  (b-c)  qRT-PCR  analysis  of  ATF4  and  CHOP  72h  after  transfection  with  siRNA directed  against 
Topoisomerase 2β, results are presented as mean of ∆∆CT ± SD (n=3). Significance level was not reached. Pictures are 
each representative for two independent experiments.  
Figure 17: No ER-stress after Topoisomerase 2β knockdown 
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4.2 Protein Inhibition with topotecan and etoposide in A549 
cells  
Although silencing of HisRS, Topo1, Topo2α and Topo2β worked out very well, no ER-
stress could be detected after knockdown of the named target genes. To investigate 
whether direct inhibition of respective proteins provokes any ER-stress or apoptosis, 
treatment  of  A549 cells  with  topotecan and etoposide was analysed.  Additionally  a 
treatment of A549 cells with a 1μM solution of Thapsigargin was performed in order to 
get a positive control for apoptosis and ER-stress.  As mentioned in 3.2.3, topotecan 
inhibits the activity of Topo1, while function of Topo2α and Topo2β can be inhibitied by 
the protein inhibitor etoposide.    
4.2.1 Analysis of ER-stress and apoptosis after topotecan treatment in A549 cells
A549 cells were treated with different concentrations of topotecan, from 50μM up to 
300μM, and incubated for 24h and 48h in each case. Surprisingly immunoblot  analysis 
of Topo1 showed a clear decrease in Topo1 protein expression on protein level for all 
concentrations and timepoints (Fig. 18). Interestingly, after 48h of incubation, also a 
downregulation of Topo2α and Topo2β could be detected. To analyze apoptosis, the 
terminal cleaved caspase form of caspase 3 was studied. In the apoptotic cell caspase 
3  is  activated  to  its  cleaved forms (17kDa and 12kDa)  [110].  Already after  24h of 
incubation,  a  slight  increase  in  cleaved  caspase  3  could  be  observed  for  all 
concentrations. After 48h of incubation an impressive upregulation of cleaved caspase 
3 was detected. Surprisingly, ATF4 expression, which marks ER-stress, seemed to be 
decreased after 48h of incubation, whereas the ER-stress marker CHOP showed a 
slight upregulation after 24h of incubation for all concentrations and after 48h for the 
higher concentrations (100-300μM) of topotecan (Fig. 18).
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IB analysis of Topo 1, Topo 2α, Topo 2β, Cleaved Caspase 3, ATF4 and CHOP 24h and 48h after  treatment with 
different  concentrations (50μM  - 300μM) of  topotecan, Vehicle served as negative control,  Thapsigargin served as 
positive  control  for  apoptosis  and  ER-stress,  β-Actin  served  as  loading  control.  Picture  is  representative  for  two 
independent experiments. (n=2)
 
To analyze effects of protein inhibition on mRNA level, sqRT-PCR and qRT-PCR were 
performed after  treatment  of  A549  cells  with  topotecan.  As Figure  24  in  Appendix 
shows,  inhibition  of  Topo  1  could  allready  be  detected  in  IB  analysis  after  8h  of 
treatment and at a concentration of 2μM of topotecan. Therefore, concentration and 
incubation time were adapted respectively and inhibition studies were performed with 
2μM and 5μM of topotecan  for 4h, 8h, 16h and 24h. In contrast to IB analysis (Fig. 24 
of appendix), inhibition of Topo1 could neither be visualized in sqRT-PCR (Fig. 19a) nor 
in qRT-PCR (Fig. 19b). As Topo2α seemed to be inhibited by topotecan on protein level 
(shown in Figure 18), expression of Topo2α was also studied on mRNA level via qRT-
PCR, but no significant downregulation of Topo2α could be quantified. With respect to 
ER-stress, no increase of ATF4 expression could be visualized in sqRT-PCR (Figure 
19a) and only a slight upregulation of ATF4 in qRT-PCR was detectable (Fig. 19d). 
However,  increasing expression of  CHOP, the known marker for  ER-stress induced 
apoptosis, could be shown impressively by sqRT-PCR (Fig. 19a) and qRT-PCR (Fig. 
19e). We were able to observe  that longer incubation times went along with ascending 
expression of CHOP for both concentrations of topotecan (2μM and 5μM). After 4h of 
Figure 18: Inhibition of Topoisomerase 1 and induction of apoptosis and ER-stress after topotecan treatment in 
A549 cells 
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topotecan treatment only a slight increase of CHOP could be observed (2μM 4h: 0,21± 
0,02;  5μM 4h:  1,21± 0,33)  and  after  24h  highest  level  of  CHOP expression  was 
detected (2μM 24h: 3,69 ± 0,26; 5μM 24h: 3,83 ± 0,3), which were significantly altered 
as compared to untreated A549 cells (UT: 0,38 ± 0,27) (Figure 19e).  
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(a)  sqRT-PCR analysis of  Topo1,  ATF4,  CHOP and XBP-1 (221/169bp: unspliced = inactive, 195/143bp:  spliced = 
active) after treatment with 2μM and 5μM of topotecan and different timepoints (4 -  24h), Vehicle served as negative 
control, Thapsigargin served as positive control  for  Apoptosis and ER-stress,  β-Actin served as loading control,  25 
cycles were performed n=2) (b-e) qRT-PCR analysis of Topo1, Topo2α, ATF4 and CHOP after treatment with 2μM and 
5μM of topotecan and different timepoints (4 – 24h), Thapsigargin served as positive control for apoptosis and ER-
stress, results are presented as mean of ∆∆CT ± SD (n=3; #p<0.05). Values were considered not significant where no  
symbols are indicated. Pictures are representative for two independent experiments. 
      
                                                         Figure 19: Induction of CHOP after topotecan treatment in A549 cells
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4.2.2 Analysis of ER-stress and apoptosis after etoposide treatment in A549 cells
A549 cells were treated with different concentrations of etoposide, from 50μM up to 
300μM, and incubated for 24h and 48h in each case. Immunoblot analysis of Topo2α 
showed a decrease of Topo2α expression for 200μM and 300μM of etoposide after 24h 
treatment and an even more downregulation of Topo2α for all concentrations after 48h 
of incubation. Regarding Topo2β, only a slight decrease in protein level was detected 
following  etoposide  treatment.  Expression  of  Topo1  remained  unchanged  after 
etoposide treatment (Fig.20a). To study apoptosis, expression of cleaved caspase 3 
was studied. Increase of cl. caspase 3 was revealed at 24h and 48h where 100μM and 
200μM of  etoposide was used (Fig.20a).  Again ATF4 expression,  which marks ER-
stress, seemed to be decreased after 48h of incubation, whereas the ER-stress marker 
CHOP showed  a  slight  upregulation  after  24h  of  incubation  for  all  concentrations. 
Immunoblot analysis for 200μM and 300μM of etoposide and shorter incubation times 
from 4h to 24h, as shown in Figure 20b, revealed decreasing expression of Topo2α 
and Topo2β with longer exposure to etoposide, although Topo2α was inhibited more 
clearly  than  Topo2β.  In  the  course  of  analyzing  ER-stress,  no  difference  in  ATF4 
expression  could  be  shown,  whereas  the  apoptotic  marker  CHOP seemed  to  be 
increased slightly after 16h and 24h for both concentrations (Fig.20b).
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(a) IB analysis of Topo2α, Topo2β, Topo1, Cleaved Caspase 3, ATF4 and CHOP 24h and 48h after treatment with 
different  concentrations  (50μM-300μM)  of  etoposide,  Vehicle  served  as  negative  control,  Thapsigargin  served  as 
positive control for apoptosis and ER-stress, β-Actin served as loading control. n=2) (b) IB analysis of Topo2α, Topo2β, 
ATF4,  CHOP  and  LC3  after  treatment  with  200μM  and  300μM  of  topotecan  with  different  timepoints  (4-24h), 
Thapsigargin served as positive control for apoptosis and ER-stress, β-Actin served as loading control. (n=2). Pictures  
are each representative for two independent experiments.
Figure 20: Inhibition of Topoisomerase 2  and induction of  apoptosis and ER-stress after etoposide treatment in 
A549 cells. 
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In order to analyze the effects of etoposide treatment on mRNA level, qRT-PCR and 
sqRT-PCR were performed and expression of topoisomerases as well  as ER-stress 
and apoptotic markers were studied. In sqRT-PCR a decrease of Topo2α after 16h and 
24h of incubation could be shown, expression of Topo2β seemed to remain unchanged 
(Fig. 21a). Longer treatment periods with etoposide revealed increased expression of 
CHOP,  whereas  no  difference  in  ATF4  expression  could  be  visualized  (Fig.21a). 
Increase in another ER-stress marker XBP-1 was also not observed after etoposide 
treatment  (Fig.21a).  As  shown in Figure 21b,  qRT-PCR and sqRT-PCR revealed a 
significant decrease in Topo2α after treatment with 300μM etoposide for 24h compared 
to untreated A549 cells (300μM 24h: -3,9 ± 0,56, UT: -0,59 ± 0,7). For Topo2β and 
Topo1 no clear decrease after etoposide treatment could be shown. Analysis of ATF4 
and CHOP via qRT-PCR again showed no difference in ATF4 expression, confirming 
the  observation  of  sqRT-PCR  (Fig.21e).  However  longer  incubation  of  cells  with 
etoposide  went  along  with  ascending  increase  of  CHOP  expression  (Fig.21f). 
Significant upregulation of CHOP compared to UT cells could be quantified for 300μM 
of etoposide for 16h ( 300μM 16h: 2,07 ± 0,17, UT: 0,17 ± 0,06) (Fig.21f). 
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(a)  sqRT-PCR analysis of  Topo2α, Topo2β, ATF4,  CHOP and XBP-1 (221/169bp: unspliced = inactive, 195/143bp:  
spliced = active) after treatment with 200μM and 300μM of etoposide and different timepoints  (4 - 24h), 25 cycles were  
performed, Vehicle served as negative control, Thapsigargin served as positive control for apoptosis and ER-stress, β-
Actin  served as  loading control.  (n=2)  (b-f)  qRT-PCR analysis  of  Topo2α,  Topo2β,  Topo1,  ATF4  and CHOP after 
treatment with 200μM and 300μM of etoposide and different timepoints (4 – 24h), Thapsigargin served as positive 
control  for  apoptosis  and ER-stress,  results  are  presented as  mean of  ∆∆CT ±  SD (n=3;  #p<0.05).  Values  were  
considered  not  significant  where  no  symbols  are  indicated.  Pictures  are  representative  for  two  independent 
experiments. 
Figure 21: Induction of CHOP after etoposide treatment in A549 cells
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4.3 Analysis of ER-stress in a patient with SSc associated ILD 
To  analyze  ER-Stress  and  apoptosis  in  CVD-ILD,  immunohistochemistry  was 
performed on lung sections of  a patient with SSc associated ILD and compared to 
healthy donor  lung sections.  Diagnosis  of  SSc associated ILD was settled  by skin 
biopsy,  barium  swallow  examination,  lung  function  test,  HRCT  and  lung  biopsy. 
Radiologically and histopathologically  an UIP pattern  was detected.  To identify ER-
stress  and  apoptosis  in  AECIIs,  immunohistochemistry  was  realized  for  p50  ATF6, 
ATF4,  pro  SP-C  and  CHOP  on  serial  sections.  SP-C  is  a  protein  exclusively 
synthesized by AECII and hence was used as a marker for AECII.
To confirm the specifity of primary antibody binding that is not a result of non-specific 
Fc receptor binding or other cellular protein interactions isotype controls with a non-
immune  immunoglobulin  of  the  same  isotype  and  concentration  as  the  primary 
antibody were performed (Fig. 25 of appendix).  
Analysis  by  immunohistochemistry  revealed  that  pro  SP-C  positive  cells  stained 
positive also for p50 ATF6, ATF4 and CHOP and thus revealed a serious induction of 
ER stress markers within AECII of patient with SSc-ILD, compared to healthy donor 
lung sections (Fig. 22 a-d).
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Figure 22: AECII specific induction of ER stress in patient with Ssc-ILD
Immunhistochemistry performed on serial paraffin-embedded lung tissue sections from human patient with SSc-ILD (a, 
b) and healthy donors (c,d) stained for p50 ATF6, pro SP-C, ATF4 and CHOP. Arrows indicate the same AECII stained 
for all four proteins. (a,c) Original magnification: 400x, scalebar, 50μm. (b,d) left: Original magnification: 100x, scalebar, 
200μm; right: Original magnification: 400x, scalebar, 50μm. 
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5. Discussion
5.1 ILD associated with collagen vascular diseases
ILDs  refer  to  a  group  of  chronic  lung  diseases  that  mainly  affect  the  epithelial, 
interstitial and vascular compartment of the lung. ILDs are characterized by fibroblast 
proliferation, collagen deposition and architectural remodeling [22]. While mechanisms 
that result in lung fibrosis are still not fully understood, there is a strong suggestion that 
ER-stress induced apoptosis caused by alveolar epithelial cell injury is the triggering 
event in pathogenesis of some forms of ILD, especially the idiopathic IIPs IPF and 
NSIP [3,19,22]. ILD is  a common pulmonary complication of CVDs, which represent a 
group of immunologically mediated inflammatory disorders. Especially in patients with 
SSc and DM/PM the developement of ILD represents a significant cause of morbidity 
and mortality [14,15,77,93, 111]. The incidence of ILD in CVD varies between 20-54% 
[79,112]. In view of frequent pulmonary involvement the present study was focussed on 
PM/DM and SSc associated ILD. 
To  define  diagnosis  of  ILD,  an  integrated  clinical,  radiological  and  pathological 
approach is necessary [3]. The most important items to determine entitiy and clinical 
significance of ILD are lung function, HRCT and lung biopsy [13].  
Autoantibodies to aminoacyl tRNA synthetase (mostly anti-HisRS) are the strongest 
predictive factor for ILD in PM/DM [71]. Autoantibodies to a glycoprotein KL-6 is also 
considered as another risk factor for ILD in PM/DM [113]. Similarly, autoantibodies to 
Topo1, Topo2α and Topo2β are strongly predictive for the development of ILD in SSc 
[7,82]. In the present study, we wished to explore the possibilitiy of an autoantibody 
induced blockade of HisRS, Topo1, Topo2α or  β in alveolar epithelial cells, possibly 
resulting in chronic AECII injury and apoptosis.  
We supposed that the binding of pathogenetic antibody directed against HisRS and 
topoisomerases results in a loss of function of the respective proteins. 
Anti-HisRS is described as an antibody directed against the cytoplasmic protein HisRS. 
Autoantibody  against  topoisomerases  are  anti-nuclear-antibodies.  They  bind  to 
contents of  the cell  nucleus,  and thus seem to inhibit  the activity of  the respective 
enzymes [114].
In Sjögren´s syndrome, an autoimmune rheumatic disease that targets salivary and 
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lacrimal  glands,  it  was  found  that  autoantibodies  mediate  apoptosis  in  the  human 
salivary gland cells in a caspase-3 dependent manner [115]. Furthermore it was shown, 
that autoantibodies to dsDNA and ribosomal P proteins, which are often found in SLE, 
are potent inhibitors of protein synthesis and are likely to mediate cellular dysfunction 
via this pathway [116]. However, blockade of HisRS and Topo 1, 2α or β by antibody-
binding has not been shown yet. Other mechanisms, how these autoantibodies may 
contribute to development of ILD in CVD, have to be taken into consideration. To this 
end,  immune  complexes  might  perpetuate  a  positive  feedback  loop  amplifying 
inflammatory responses [117]. IgG-mediated activation of complement is an important 
defense  mechanism  of  the  innate  immune  system  to  protect  against  infections. 
However, the same mechanisms can drive severe and harmful inflammation, when IgG 
antibodies  react  with  self-antigens  in  solution  or  tissues,  as  described  for  several 
autoimmune diseases. More specifically, IgG immune complexes can activate all three 
pathways  of  the  complement  system,  resulting  in  activation  a  panel  of  different 
complement receptors on innate and adaptive immune cells. Importantly, complement 
is often co-expressed on inflammatory immune cells such as neutrophils, monocytes, 
macrophages  or  dendritic  cells  and  act  in  concert  to  mediate  the  inflammatory 
response in autoimmune diseases   [118].
It  is  currently  unclear,  how  the  presence  of  autoantibodies  contributes  to  the 
development of CVD-ILD, but like in other forms of ILDs like IPF, which is the most 
common form of idiopathic ILD, chronic injury of the alveolar epithelium is currently 
discussed as a possible event [21,45]. In full agreement, it was reported that patients 
with  SSc  associated  ILD  demonstrated  breach  of  the  epithelial  barrier  [119].  The 
increase in KL-6, a glycoprotein that is exclusively found on the surface of alveolar 
epithelial  cells in serum and bronchoalveolar  lavage (BAL) of patients with different 
forms of CVD-ILD is also indicative of severe epithelial injury. On the same line, it was 
suggested that the alveolar epithelial cell-endothelial cell compartment is the site of the 
initial injurious process in SSc associated ILD [86]. 
Due to the scarce patient material  and the need for  in vitro studies to identify and 
understand the molecular mechanisms underlying different ILD associated CVD, we 
focused  our  study  primarily  on  HisRS,  Topo1,  Topo2α and  Topo2β,  being  the 
autoantibody  targets  in  DM/PM and  in  SSc,  asking  for  the  possibility  that  loss  of 
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function of these proteins could cause alveolar epithelial stress similar to IPF.
5.2 ER-stress and apoptosis of AECII in CVD-ILD  
As Günther et al. [47] reported, chronic injury of AECIIs is increasingly accepted as an 
elementary event in pathogenesis of IPF. In 1988 Myers and Katzenstein [24] already 
emphasized the role of epithelial necrosis and alveolar collapse in pathogenesis of UIP. 
However the hypothesis that development of IPF was due to an inflammatory process 
[40]  prevailed  until  2006,  when  Selman and  Pardo  [120]  reintroduced  the  topic  of 
epithelial cell injury in IPF. Now it is assumed that injury to epithelial alveolar cells, in 
particular AECII, underlies abnormal epithelial repair in IPF [46]. On this line, Korfei et 
al. [42] recently showed that AECII undergo ER-stress and apoptosis in sporadic IPF. 
The ER plays a central role in folding and secretion of newly synthesized proteins [57]. 
Accumulation of unfolded proteins in the ER caused by impairment of protein folding 
and  processing,  activates  the  UPR with  the  primary  purpose  of  aiding  the  cell  to 
improve the protein  folding and to  attain  homeostasis  again  [55,59].  UPR involves 
activation of IRE1α, PERK and ATF6 [60]. PERK phosphorylates eIF2α which reduces 
the protein load on the ER. IREα induces splicing of XBP1 in order to produce the 
homeostatic transcription factor XBP1s [61]. ATF6 and XBP1s increase transcription of 
genes which  enhance  ER size  and  function  [62].  By  phosphorylation  of  eIF2α the 
translation of ATF4 is stimulated, which again leads to transcription of different pro-
survival  genes  [63].  This  ER-stress  reaction  generally  helps  the  cell  to  survive. 
However, if the stress condition is overwhelming or prolonged, the cell will be driven to 
apoptosis [60,64]. 
The initial focus of this study was to downregulate expression of HisRS, Topo1, Topo2α 
and Topo2β and to analyze the subsequent effects on A549 cells like ER-stress and 
apoptosis. In spite of quite successful silencing of the respective genes, no induction of 
ER-stress  could  be  detected  in  A549  cells.  Such  observation  deserves  further 
discussion:  Firstly,  it  has to be noted that the still  remaining protein after respective 
gene knockdown might be sufficient to perform its functions in the cell. Densitometric 
analysis  revealed  a  considerable  magnitude  of  remaining  protein  after  silencing  of 
HisRS, Topo1 and Topo2ß. In case of Topo2α, only a very small amount of remaining 
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protein could be measured densitometrically (0.88%). Nevertheless, only a slight and 
non-significant  ER-stress  response  could  be  revealed  after  knockdown  of  Topo2α. 
Secondly,  even in  case of  a complete loss of  the target  protein,  it  may take some 
additional  more  time  until  cellular  stress  evolves.  Thirdly,  it  should  be  taken  into 
account  that  the autoantibodies in  CVD-ILD may only provoke a moderate level  of 
cellular stress and secondary hits such as infection and smoking may be needed for 
apoptosis and development of lung fibrosis. Kropski et al. [121] recently emphasized 
the role of herpesvirus infection as a second hit in IPF and reported that herpesvirus 
infection induces or worsens lung fibrosis when combined with immunodeficiency or 
other injurious stimuli. They consider induction or modulation of ER stress responses 
as one potential mechanism through which herpesvirus infection may contribute to the 
pathogenesis of IPF.
We then directed our experiments towards pharmacological inhibition of the proteins of 
interest.  A549  cells  were  treated  with  etoposide  and  topotecan  in  order  to  inhibit 
function of Topo1 and Topo2. Etoposide is a semisynthetic derivative of podophyllotoxin 
that exhibits antitumor activity. It impairs DNA synthesis and prevents re-ligation of DNA 
strands by forming a complex with Topo2 and DNA. Thus, repair of DNA by Topo2 is 
inhibited  and  apoptosis  of  cancer  cells  can  be  promoted  [101].  Topotecan  is  an 
antineoplastic  agent  used to treat  ovarian cancer.  It  works  by inhibiting  function of 
Topo1. Topotecan binds to the Topo1-DNA-complex and thus prevents religation of the 
single  strand  breaks  [102–104]. Due  to  the  lack  of  appropriate  pharmacological 
inhibitors, inhibition of HisRS could not be realized.
Treatment of A549 cells with topotecan lead to a decrease in Topo1 expression on 
protein  level,  whereas  RNA  levels  of  Topo1  seemed  to  be  unaffected  by  such 
approach.  Interestingly, after 48h of incubation, also a downregulation of the proteins 
Topo2α and Topo2β could be detected. Up to now topotecan was only known as an 
inhibitor of Topo1. Impressive upregulation of cleaved Caspase 3 and CHOP in A549 
after treatment with topotecan strongly suggested an apoptotic response.  Caspases 
are  crucial  mediators  of  programmed  cell  death.  Among  them,  caspase-3  is  a 
commonly  activated  death  protease,  catalyzing  the  specific  cleavage  of  many  key 
cellular proteins [110]. Especially the observed upregulation of CHOP on RNA level 
lead  to  the  assumption,  that  topotecan  provokes  an  ER-stress  mediated  apoptotic 
response in A549 cells. Recent studies revealed that CHOP is one of highest inducible 
genes during ER stress  [122,123].  Also,  inhibition  of  Topo2α and Topo2β following 
treatment of A549 cells with etoposide showed significant increase of CHOP on RNA 
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level and thus again provided indication of ER-stress induced apoptosis. Surprisingly, 
after  treatment  of  A549  cells  with  etoposide,  downregulation  in  Topo2α  was  also 
noticed on RNA level.  Effects of etoposide on Topo2 mRNA are not described yet and 
require further studies. 
Significant induction of CHOP after treatment with topotecan and etoposide indicated 
that ER-stress and apoptosis are triggered after inhibition of topoisomerases. Su and 
Kilberg [65] identified CHOP as an interacting partner of ATF4. Previously Bruhat et al. 
[124]  showed that  expression of  CHOP is rapidly induced through ATF4-dependent 
transcription.  Surprisingly,  our  experiments  showed  that  CHOP is  induced  despite 
unaffected expression of ATF4. Upregulation of CHOP next to seemingly unchanged 
ATF4 expression may arise from an inhibitory effect of CHOP on ATF4 function, as 
already  discussed  by  Su  and  Kilberg  [65].  Another  possible  reason  for  exclusive 
induction of CHOP could be the existence of other pathways playing a role in activation 
of  CHOP. Gotah et  al.  [125]  as well  as Paschen et  al.  [64]  mentioned ATF6 to be 
another activator of CHOP. Bruhat et al. [124] demonstrated that at least two pathways, 
one  leading  to  ATF4  induction,  and  one  leading  to  ATF2  phosphorylation,  are 
necessary to induce CHOP expression. To gain certainty concerning the mechanism of 
CHOP activation  after  treatment  of  A549 cells  with topotecan and etoposide,  other 
mechanisms like induction of ATF4, ATF6 and ATF2 have to be investigated intensively 
in future experiments. 
To examine whether AECIIs are actually the cells of interest in developement of CVD 
associated  lung  fibrosis,  lung  sections  of  patient  with  SSc  associated  ILD  were 
immunhistochemically  analyzed.  Chronic  injury  of  AECIIs  is  considered  key  in 
pathogenesis of IPF [22,46]. The injured alveolar epithelium can not be re-epithelized 
which  leads to disruption of the epithelial integrity in the alveoli. As a consequence 
profibrotic cytokines and growth factors are released by the damaged epithelial cells 
[40,44]. Korfei et al. [42] demonstrated that a severe ER Stress response in the AECIIs 
underlies apoptosis in patients with IPF. By performing IHC in lung sections of patient 
with  SSc-ILD  the  present  study  confirmed  AECIIs  to  be  also  of  interest  in  CVD 
associated ILD. We identified AECII specific induction of ER-stress and apoptosis in 
CVD-ILD. Showing that ER-stress and apoptotic responses in AECIIs also play a key 
role in CVD associated ILD and the positive ER-stress response in A549 cells after 
protein  inhibition  with  topotecan  and  etoposide  entail  the  strong  assumption  that 
autoantibodies found in CVD somehow trigger the cellular stress mechanisms in AECII, 
which in turn contribute majorly to the development of lung fibrosis.       
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5.3 Conclusions and future perspectives in regard to CVD-ILD 
pathogenesis
Experiments  of  this  study  were  performed  in  order  to  test  the  hypothesis  that 
autoantibodies  against  HisRS,  Topo1,  Topo2α  and  Topo2β cause  ER-stress  and 
apoptosis in AECII by blocking respective target genes and thus trigger development of 
lung fibrosis. Data are received from in vitro experiments with A549 cells. The used cell 
line  is  well  established in  culture and frequently  used for  basic  research indicating 
reactions of the human AECIIs. 
It has to be emphasized, that the obtained results are preliminary data. First of all, it 
was  important  to  realize  successfull  gene  silencing  and  protein  inhibition.  To gain 
certainty  regarding  the  effects  on  apoptosis  and  ER-stress  after  respective  gene 
silencing  and  protein  inhibition,  a  higher  number  of  independent  experiments  is 
required in further studies. 
One issue which also has to be clarified in future is if binding of autoantibodies against 
HisRS and topoisomerases indeed results in a loss of function of the target proteins. 
Other  mechanisms  caused  by  the  antigen-antibody-complexes,  like  complement 
activation or other, more complex, immunological reactions, also have to be taken into 
consideration concerning development of ILD in CVD. 
To identify, if ER-stress and apoptosis in AECIIs are indeed caused by autoantibodies 
against  HisRS, Topo1, Topo2α or Topo2β and thus lead to developement of  ILD, a 
worthwile research focus would be to check binding pattern of purified autoantibodies 
against HisRS, Topo1, Topo2α or Topo2β in order to confirm AECIIs to be the target 
cells for the autoantibodies in the lung. 
Another interesting issue would be to check, if alveolar epithelial knockdown of HisRS, 
Topo1, Topo2α or Topo2β triggers developement of ILD by analyzing the consequeces 
of gene silencing on fibroblastproliferation and matrixproduction. Furthermore the need 
for secondary hits in development of lung fibrosis such as viral infections have to be 
investigated.    
Further experiments are required to analyze if,  in case of a complete loss of target 
protein, there still exists some secretory activity in the cell and if more time is needed 
until cellular stress evolves. Therefore transient and stable transfections in vitro and in 
vivo have to be performed. Future plan of our group is to work with inducible, AECII 
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specific  knock out  mice and check,  if  silencing of  Topo 1/2 and HisRS  in vivo can 
contribute to development of lung fibrosis. 
  
From the results of the present study it can be concluded that pathogenesis of CVD 
associated ILD may include ER-stress and apoptosis of  AECIIs. This is reinforced by 
the finding of an induction of ER-stress and apoptosis after inhibition of topoisomerases 
in vitro.  The further elucidation of  the precise mechanisms, how the autoantibodies 
mediate these reactions in AECIIs, still deserves further investigations. 
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6.1 Additional figures
A549 cells were transfectes with siRNA directed against  Topo1 (a),  Topo2α (b)  and Topo2β (c)  and knockdown of 
respective genes was checked by sqT-PCR 48h after transfection. Mock (transfection with transfection reagen without 
any siRNA and scrambled (non targeting siRNA) served as negative controls, 30 cycles were performed, β-Actin served 
as loadig control.
Figure 23: Silencing of Topo1, Topo2α and Topo2β
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IB analysis of Topo 1, Topo 2α, ATF4, CHOP and LC3 after treatment with 2μM and 5μM of topotecan and different 
timepoints (4-24h), Vehicle served as negative control, Thapsigargin served as positive control for apoptosis and ER-
stress, β-Actin served as loading control.
Immunhistochemistry  performed on  serial  paraffin-embedded  lung  tissue  sections  from healthy  donors  stained  for 
isotype control antibodies. Original magnification: 400x, scalebar: 50μm 
Figure 24: Inhibition of Topo1 after topotecan treatment in A549 cells.
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Figure 25: Isotype controls
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6.2 Primer sequences
Gene Sequences (5' → 3')
ATF4 for GAT AGG AAG CCA GAC TAC ACT G
rev GAG ACC CCA GAT AGG ACT CTG
β-Actin (sqRT-PCR) for ACC CTG AAG TAC CCC ATC
rev CAG CCT GGA TAG CAA CGT AC
β-Actin (qRT-PCR) for CAG AGC CTC GCC TTT GCC G
rev GAC GAG CGC GGC GAT ATC AT
CHOP for ACT CTC CAG ATT CCA GTC AGA G
rev GCC TCT ACT TCC CTG GTC AG
DDB1 for TAT CCA GAT CAC TTC AGC ATC G
rev GAT GGA GCG AGG AAT GAT CTC
HisRS for CTA TGA GGC AGT GCT GCT AC
rev CAG CAG CTC AGC CTT GAT C
p53 for GCA CAT GAC GGA GGT TGT G
rev AGT GTG ATG ATG GTG AGG ATG
Topo1 for CCA CAA CGA TTC CCA GAT CG
rev TGG ACT AGA GAA GCC ATT TTC C
Topo2α for TGG TGA TAA ATG GTG CTG AAG G
rev GTT ATG AGA GGA GGT GTC TTC TC
Topo2β for ATG CTA GAT GGC CTG GAT CC
rev GTC CAG CAG CTT CTG CTT G
VCP for CCA AGG GAG TTC TGT TCT ATG G
rev GAG GAT GGC AGG ATC AAT GAT G
XBP1 for GTT GAG AAC CAG GAG GAG TTA AGA
rev CAG ACT CTG AAT CTG AAG AGT C
XBP1 for GAT GCC CTG GTT GCT GAA
rev GAG TCA ATA CCG CCA GAA TCC
Table 19: Primer sequences
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6.3 Dissociation curves
Figure 26: Dissociation curves
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